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List of Abbreviations 
 
AA amino acid 
Ala alanine 
Ap ante partum 
Arg arginine 
Asn asparagine 
Asp aspartic acid 
BCAA branched chain amino acids 
BF breastfed 
Car carnosine 
CE collision energy 
CID collision induced dissociation 
Cit citrulline 
CLA conjugated linoleic acid 
Cntr control  
CXP collision cell exit potential 
Cys cystine 
Cysta cystathionine 
DP declustering potential 
EP entrance potential 
FIA flow injection analysis 
FP focusing potential 
Gln glutamine 
Glu glutamic acid 
Gly glycine 
HLys hydroxylysine 
HP high protein 
HPLC high performance liquid chromatography 
HPro hydroxyproline 
IGF-1 insulin-like growth factor 1 
Ile isoleucine 
IS internal standard 
Leu leucine 
LP low protein 
Lys lysine 
Met methionine 
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MHis methylhistidine 
mo month 
MS mass spectrometry 
MSUD maple syrup urine disease 
mTOR mammalian target of rapamycin 
mTORC1 mammalian target of rapamycin complex 1 
mTORC2 mammalian target of rapamycin complex 2 
Orn ornithine 
Phe phenylalanine 
PKU phenylketonuria 
Pp post partum 
Pro  proline 
Ser serine 
Thr threonine 
TMR total mixed ration 
Trp tryptophan 
Tyr tyrosine 
Val valine 
Wk week 
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1 Introduction 
 
Amino acids (AA) are the building blocks of proteins and also serve as energy sources. 
They play an important role in the biochemistry of any living organism. Analysis of 
amino acids profiles is therefore an important tool for the study of metabolic regulation 
and dysregulation. Acknowledging their central role in energy and protein metabolism, 
we aimed at developing a high-throughput method for the quantification of all 
proteinogenic amino acids plus the urea-cycle related amino acids ornithine and 
citrulline. As part of a targeted metabolomics platform established at the Dr. von 
Hauner Children´s Hospital, a high-throughput method was developed for a variety of 
applications in metabolic research, including cohort studies, intervention trials and 
experimental settings. The desired method had to meet the criteria of being (a) cost-
effective for a large number of samples, (b) robust in terms of repeatability over 
multiple batches, (c) sensitive enough to obtain accurate quantification form very 
limited samples volumes, (d) inherently selective to enable validation of analyte signals 
in every sample. 
This doctoral thesis project achieved development of a new LC-MS/MS method for AA 
determination meeting all of these requirements. The presented protocol combines 
derivatization and ion-pairing to a highly sensitive and robust method which allows 
quantitative analysis of all proteinogenic AA, citrulline and ornithine. This work 
describes method optimization and thorough validation according to widely accepted 
industry standards and subsequent application to diverse projects in clinical research 
and dairy science. Both applications differed considerably regarding background, 
sample types and objectives, but AA analysis was performed by the same, broadly 
applicable new method.  
As a first example, samples from the CHOP European Childhood Obesity trial where 
analyzed, where protein intake in the first year of life was examined for its relation to 
rapid weight gain in early childhood (1). More than 1000 healthy, formula-fed infants 
were randomly assigned to receive cow-milk–based and follow-on formulas with lower 
(LP) or higher protein (HP) contents for the first year. Both groups were compared to 
breast fed (BF) infants. We analyzed serum AA of HP-, LP- and BF groups and 
compared AA profiles between these nutritional intervention groups. 
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A second application example of the new methodology was a feeding intervention trial 
in the field of dairy science. Dairy cows were either supplemented with conjugated 
linoleic acid (CLA group, n=10) and or with linoleic acid (control group, n=10) from two 
weeks before to nine weeks after expected calving. The aim of the study was to 
analyze the relation between CLA supplementation and AA profiles in blood samples 
taken at eight consecutive time points over the intervention period. 
METHOD DEVELOPMENT 
9 
 
  
2 Development of a method for quantification of 22 amino 
acids 
 
2.1 Background 
 
The discovery of AA began with the isolation of asparagine (Asn) from asparagus juice 
by Louis-Nicolas Vauquelin and Pierre Jean Robiquet in 1806 (2). Many years passed 
until all AA were characterized. Twenty AA are directly encoded in the genetic code 
and called proteinogenic AA. Asn, a non essential AA, is synthesized by the human 
body as well as alanine (Ala), arginine (Arg), aspartic acid (Asp), cysteine (Cys), 
glutamine (Gln), glutamic acid (Glu), glycine (Gly), proline (Pro), serine (Ser) and 
tyrosine (Tyr). Essential AA cannot be synthesized by humans and need to be up taken 
from dietary sources. Those are histidine (His), isoleucine (Ile), leucine (Leu), lysine 
(Lys), methionine (Met), phenylalanine (Phe), threonine (Thr), trypthophan (Trp) and 
valine (Val). Arg, Cys and Tyr are semi-essential and need to provided by food during 
early childhood (3). Semi-essential AA can be synthesized by the human body but 
under certain conditions (growth, strong physical strain) a number of AA are essential 
and must be taken by food.  
AA play an important role in the biochemistry of any living organism. They function as 
building blocks of proteins and also as energy sources. Some AA in proteins act as 
catalysts, others serve for storage and transport, while still others are antibodies for our 
immune system. Tyr is a precursor of adrenaline which regulates moods and stimulates 
metabolism and the nervous system (4). Arg is involved in tumor metabolism (5) and 
His is essential for the growth and regeneration of tissues and needed for the 
production of red and white blood cells. AA play a central part in the human organism. 
Published studies have shown changing AA profiles in various diseases e.g. 
phenylketonuria (6), chronic granulomatous disease, cystinuria (7), Hartnup disease or 
maple syrup urine disease, just to name a few monogenetic disorders (8).  
The usefulness of AA profiling is exemplarily illustrated by newborn screening which is 
performed after delivery to detect metabolic diseases at an early stage (9).  During 
further life, AA profiling is also essential for diseases like metabolic syndrome, obesity 
and diabetes. Therefore, metabolic profiling is supposed to further our insights into 
pathophysiology and therapeutic strategies of these disorders. Recent studies show 
METHOD DEVELOPMENT 
10 
 
new possibilities of using plasma AA analysis as biomarker discovery tools by 
generating diagnostic indices through systematic computation. Insulin resistance has 
been reported to result in major disturbances of AA profiles (10). On the other hand, 
amino acid uptake has been shown to exert anabolic effects independent form insulin 
signaling, offering a new rationale for potential therapeutic intervention in patients with 
reduced insulin secretion (11). AA profiling of biological samples could be used to 
generate indices of diseases (Table 1). Different types of cancer patients (colorectal, 
breast, lung) show an altered amino acid profile compared to healthy subjects (12, 13). 
In obese humans plasma branched chained AA (BCAA) are markedly increased 
compared to lean humans (14). AA could be useful indicators for facilitating nutritional 
management of specific physiological and pathological states. 
Table 1: Effects of metabolic diseases on AA levels in urine or plasma (↑increased values 
↓decreased values) 
 Ala Arg Asn BCAA Cit Cys Glu His Lys Met Orn Phe Ser Thr Trp Tyr 
PKU            
 
    
Cystinuria  
 
   
 
  
 
 
 
     
Hartnup 
disease  
 
  
  
  
   
     
MSUD    
 
            
Obesity    
 
            
Colorectal 
cancer 
   
Ile  
 
 
 
  
 
 
 
 
 
 
 
Breast 
cancer 
 
 
 
 
  
 
  
     
  
Liver 
disease 
   
 
       
 
  
  
 
Analysis of AA profiles is a centrally important tool for studying metabolic regulation 
and dysregulation. It is essential to develop methods for larger clinical research trials 
with cost-effectiveness for a high number of samples, robustness in terms of 
repeatability over multiple batches and inherent selectivity to enable validation of 
analyte signals in every sample. Additionally, time efficient and comprehensive 
quantification of AA from small plasma volumes continues to be a challenge. Different 
determinations of AA are known. The most established methodology, the amino acid 
analyzer has long run times of 120 min and is not suitable for large number of samples 
or for large clinical trials (15). In the last few years, much effort was spent on 
developing high-throughput methods (16-18). Several analytical HPLC methods have 
been developed for amino acid quantification, coupling liquid chromatography with 
optical detection (UV, fluorescence) or mass spectrometry (MS) (19). Mass 
spectrometry (MS) plays an important role as the detector for HPLC due to the 
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selectivity, which can distinguish analytes by their mass-to-charge ratio (m/z). LC-
MS/MS has afforded gains of selectivity and sensitivity by multiple reaction monitoring 
(MRM). Capillary electrophoresis (CE) does not require derivatization (20). Using ion-
pairing is another option to separate underivatized AA (21). To achieve more sensitivity 
and selectivity, derivatization reagents like o-phthalaldehyde, phenylisothiocyanate, 
alkyl chloroformate (19) or butanolic HCl (18, 22) were applied. Also GC-MS, 
hydrophilic interaction chromatography (HILIC), NMR and direct infusion have been 
used for amino acid analysis (19). 
Acknowledging their central role in energy and protein metabolism, we aimed at 
developing a high-throughput method for the quantification of AA in clinical trials. To be 
useful in larger clinical research trials as part of a targeted metabolomics platform, the 
method should meet the following criteria: cost-effective for a large number of samples, 
robustness in terms of repeatability over multiple batches, sensitively to obtain accurate 
quantification from very limited samples volumes, inherent selectively to enable 
validation of analyte signals (23). 
Here, we present a protocol combining derivatization and ion-pairing to a highly 
sensitive and robust method (23). The established method provides a reduction of 
sample volume, ion suppression and analyzing time, while enhancing sensitivity with 
high resolution chromatographic separation and optimal peak shapes for all analytes. 
The process allows the quantitative analysis of 22 AA (all proteinogenic AA, citrulline 
and ornithine) using a LC-MS/MS system (AppliedBiosystems/Sciex API 2000). Over 
time, seven non proteinogenic AA have been added to the method: Anserine, 
carnosine, cystathionine, hydroxylysine, hydroxyproline, methylhistidine and sarcosine.  
 
 
2.2 Experimental 
2.2.1 Instrumentation 
The HPLC part of the analytical apparatus of a HPLC 1100 system from Agilent 
combined a binary pump, an autosampler and a column oven with a 10-port column 
switching valve. Mass spectrometric detection was done with an 
AppliedBiosystems/Sciex API 2000 triple quadrupole in the sensitive MRM mode, 
equipped with an Atmospheric Pressure Chemical Ionization (APCI) source which was 
operated in positive ion mode. Data handling and quantification were done with 
AppliedBiosystems/MDS Analyst 1.5 software using ’Scheduled MRM’ algorithm, which 
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allows optimization of effective dwell time by scheduled monitoring of mass transitions 
only within predefined retention time windows. Chromatographic separation occurred 
on a single Waters XBridge C18 column, 2.1 mm * 150 mm, 3.5 µm (Waters, Eschborn, 
Germany). 
 
2.2.2 Reagents 
Amino acid standards were purchased from Sigma (Taufkirchen, Germany) in a mix of 
17 AA and ammonium chloride. AA in this standard solution are 2.5 μmoles per mL in 
0.1 N HCl, except for L-cystine at 1.25 μmoles per mL. L-asparagine anhydrous and L-
tryptophan were supplied from Fluka (Taufkirchen, Germany). L glutamine, DL-citrulline 
and DL-ornithine were supplied from Sigma (Taufkirchen, Germany). Internal standards 
were obtained from Cambridge Isotope (Andover, MA, USA) in a mix of 12 stable 
isotope labeled AA (Table 2). Furthermore, L-tryptophan (indole D5) and L-asparagine 
(U-15N2) were also obtained from Cambridge Isotope (Andover, MA, USA). Methanol 
and water (both LC-MS grade) were purchased from J.T.Baker (Griesheim, Germany). 
Heptafluorobutyric acid (HFBA) was purchased from TCI Europe (Zwijndrecht, 
Belgium). Hydrogene chloride (3M) in 1-butanol and formic acid (LC-MS grade) were 
supplied from Fluka (Taufkirchen, Germany). Plasma controls (ClinChek® Plasma 
Control, Lyophilized, for AA, Levels I and II) were obtained from Recipe (Munich, 
Germany). 
Table 2: Composition of labeled internal standard 
Name of internal Standard Labeling of internal Standard 
L-Alanine L-Alanine (2.3.3.3-D4, 98%) 
L-Phenylalanine L-Phenylalanine (ring-13C6, 99%) 
L-Leucine L-Leucine (5.5.5-D3,  98%) 
L-Valine L-Valine (D8, 98%) 
L-Arginine L-Arginine:HCL (5-13C.99%, 4.4.5.5.-D4, 95%) 
L-Citrulline L-Citrulline (5.5-D2, 98%) 
DL-Glutamic acid DL-Glutamic acid (2.4.4-D3, 97%) 
L-Tyrosine L-Tyrosine (ring-13C6, 99%) 
L-Ornithine L-Ornithine:HCL (5.5-D2, 98%) 
L-Methionine L-Methionine (methyl-D3, 98%) 
L-aspartic acid L-aspartic acid (2.3.3-D3, 98%) 
Glycine Glycine (2-13C, 99%, 15N, 98%) 
L-Asparagine L-Asparagine (15N2, 98%) 
L-Tryptophan L-Tryptophan (Indole D5, 98%) 
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2.2.3 Method Development 
Our method based on the chemical derivatization of AA to amino acid butyl esters (24). 
Schulze analyzed amino acid butyl esters in new born screening for inborn errors of 
metabolism. Figure 1 shows the derivatization with n-butanolic HCl of alanine to 
alanine butyl ester as an example.  
 
Figure 1: Derivatization of alanine to alanine butyl ester 
 
In the first step of development we optimized several potentials and energies such as 
declustering potential (DP), entrance potential (EP), collision energy (CE), collision cell 
exit potential (CXP), focusing potential (FP) and ion source temperature of MRM 
compounds with flow injection analysis (FIA) using the quantitative optimization mode 
of the Analyst software for improving better intensity. Optimized parameters were 
merged to one method including all MRM transitions and parameters of the analyzed 
AA. This method is used for chromatographic separation using Xbridge C18 reversed 
phase column with different gradients of water and acetonitrile. One of the first 
presentable chromatogram of AA is shown in figure 2. Therefore samples were 
prepared by Schulze and analyzed with a flow rate of 300 µL/min and a gradient of 
water and acetonitrile (24)(Table 3). 
Table 3: Composition of mobile phase 
Time [min] % of water % of Acetonitrile 
0 90 10 
3 90 10 
17 85 15 
45 0 100 
47 0 100 
49 90 10 
54 90 10 
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Figure 2: chromatogram of 22 AA using Xbridge C18 with a runtime of 54 min 
 
Figure 2 shows very sharp peaks but polar peaks like Asn, Arg, His and Orn were 
eluted within 2 min due to insufficient retardation by column. To separate early eluting 
peaks from the ion suppression zone, peaks have to elute after 3 min. Details about ion 
suppression are given in section 2.3.3.  
The worldwide shortage of acetonitrile in 2009, forced us to use methanol as 
precipitation reagent instead of acetonitrile. Mobile phases, precipitation reagent was 
replaced with methanol and coelutions were separated from analytes much better 
using methanol. Using acetonitrile, we observed coelution in EDTA plasma of Asp. 
Using methanol coelution was clearly separated from Asp.  
A further improvement of chromatography was achieved by the use of ion pair reagent. 
This chemical can be retarded longer at stationary phase due to the strong bond of the 
alkyl chain with stationary phase to exclude analytes from the ion suppression zone. 
Positive loading of reagent is coupled to complex with charged compounds. We used 
HFBA, an anionic ion pair reagent which is used in reversed phase HPLC (Figure 3). 
0.1% is added to the mobile phase A (water) and B (methanol).  
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Figure 3: Chemical structure of HFBA 
 
Figure 4 shows a chromatogram of one plasma sample using HFBA as ion pair 
reagent. Compared to figure 2 retention times of analyte shift backward with excellent 
peak shapes whereby Asn eluted at 4 min as the first peak in chromatogram.  During 
method development, run time of chromatograms was reduced to 16 min for one 
sample.   
 
Figure 4: chromatogram of 22 AA using Xbridge C18 and HFBA with a runtime of 16 min 
During method development different columns were tested for chromatographic 
separation of AA. Especially Agilent Zorbax C18 and Phenomenex PFP column were 
trialed to get better separation results. Agilent Zorbax C18 is well suited for 
chromatography but the major disadvantage is the inadequate column stability due to 
very acidic pH levels. The use of PFP column shows moderate retardation and less 
peak sharpness of some AA. Both columns were not suitable for clinical trials with large 
number of samples. Advantages of stability and peak sharpness enable the Xbridge 
column for combination of butylation and ion pair chromatography. In summary, we 
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measured more than 5000 samples with the same Xbridge column which is profitable 
for large scale studies.  
In some experiments, the addition of acid to the precipitation reagent leads to a better 
reproducibility. Hence various precipitation reagents have been tried in order to 
optimize quantification. For testing, calibration curves of all standard concentration 
were done and correlation coefficient r was determined. Table 4 shows all correlation 
coefficients less than 0.995. Especially methanol with 2% HCL shows the highest 
correlation coefficients for all AA (r > 0.995) and is perfectly used as precipitation 
reagent.  
Table 4: Correlation coefficient 0.995 of AA of different precipitation reagents 
Precipitation reagent Correlation coefficient r < 0.995 
MeOH  His, Ser, Gln, Lys  
MeOH + 2% HCL  -  
ACN  Gly, His, Ser, Gln, Lys, Thr  
ACN + 2% HCL  His, Pro  
MeOH + ACN + H2O + 2% HCL  His, Orn, Trp, Ser, Lys  
ACN + TFA (0.05%) + FA (0.1%)  Gly, His, Ser, Gln, Lys  
 
External standard preparation has been optimized and improved in the course of time. 
Two stock solutions (1 and 2) were prepared. External standard solution 1 consisted of 
premixed solution of 17 AA (concentration of 2.5 mmol/L). For solution 2, Ala, Cit, Gln, 
Orn and Trp were weighed and diluted to a concentration of 2.5 mmol/L.  It should be 
emphasize that solution 1 and 2 were mixed in the opposite ratio where low values of 
S1 are mixed with high values of S2 and the other way around. Finally, following 
calibration concentration were prepared for quantification of AA (Table 5).  
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Table 5: External standard concentration of solution 1 and 2 
Number of external 
standard 
Ext. Standard  
Concentration of  
solution 1 (S1) 
 
Ext. Standard  
Concentration of 
 solution 2 (S2) 
K01 10 µM 200 µM  
K02 25 µM 100 µM 
K03 50 µM 50 µM 
K04 100 µM 25 µM 
K05 200 µM 10 µM 
K06 CP1 CP1 
K07 CP1 + 25 µM CP1 + 25 µM 
K08 CP2 CP2 
 
Figure 5 shows a perfectly measured calibration curve of Ala with r = 0.997 after 
analyzing 81 unknown samples from a clinical trial.  
 
Figure 5: Calibration curve of 8 external standards for Ala, r= 0.997 
 
2.2.4 Preparation of external- and internal standard, elution solvent, QC- and 
plasma samples 
Asparagine-, citrulline-, glutamine-, ornithine- and tryptophan powder were weighed to 
a concentration of 2.5 mmol/L (solution A).This solution was added to a premixed 
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solution of 17 AA (concentration of 2.5 mmol/L), purchased from Sigma Aldrich, to a 
final stock solution of 0.5 mmol/L. The stock solution was diluted in water to final 
standard calibration concentrations of 10, 25, 50, 100 and 200 µmol/L. Furthermore, 2 
plasma control levels, purchased from RECIPE, were prepared. The lower level of 
plasma control was spike using 25 µmol/L of standard solution. To construct the 
calibration curve, we need a total of 9 samples including 5 levels of aqueous standard 
solution, 2 levels of matrix samples, 1 spiked matrix sample and 1 blank.  
The internal standard, purchased from Cambridge Isotopes, contains of 12 stable 
isotope labeled AA and was diluted with 1 ml of methanol/water (1:1). After mixing for 
15 min in the ultra sonic bath, the solution was completely transferred in methanol to a 
final volume of 200 ml. Absolute concentrations of internal standards is about 2.5 
µmol/L expect for glycine with 12.5 µmol/L. Aliquots of 10 ml are stored at -85°C in 
glass bottles.  
Anionic ion pair reagents Hepta Fluoro butyric acid (HFBA) was added to the mobile 
phase to achieve a better interaction between analyte and stationary phase. Therefore, 
a solution of HFBA (0.5 mol/L), purchased from TCI Europe, was diluted in mobile 
phase A (water) and mobile phase B (methanol) to a final concentration of 0.5 mmol/L.  
For sample preparation a fresh precipitation reagent is used. For a 96 well plate 30 ml 
methanol was added to 10 ml of internal standard, 4 ml water and 880 µL HCL. 450 µL 
of this solution was added to a 96 * 1 ml deep well plate using a stepper pipette and 10 
µL of sample or standard was added to the precipitation reagent. After shaking for 20 
min, the deep well plate is stored for 60 min at +5°C and then centrifuged for 10 min at 
2300*g at +5°C. A supernatant of 200 µL was transferred in a 96 * 0.3ml well plate 
using a multi-channel pipette and dried completely under nitrogen. For derivatization, 
100 µL of hydrogene chloride (3M in 1-butanol) were pipetted to each sample and the 
plate was sealed with PCR adhesive film and incubated for 15 min at 60°C in a thermo 
shaker. After evaporation, the samples were filled with 100 µL injection solvent (80% 
water, 20% methanol, 0.1% formic acid) and final shaking for 10 min.  
 
2.2.5 HPLC and MS settings 
From the prepared samples, 10 µl were injected into the HPLC system. The gradient 
system used a single reversed phase column (Waters XBridge C18, 2.1 mm * 150 mm, 
3.5 µm) with a flow rate of 0.3 ml/min and a column oven temperature of 40°C. The 
HPLC gradient was increased linearly from 25 % B to 75% B within 15 min. After 
isocratic elution for 1.5 min the gradient returned to initial conditions till 16.5 min, 
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followed by isocratic equilibration until 21 min. Total time from injection to injection 
accounted for 22 min (including 0.8 min autosampler operation time). 
Mass Spectrometric settings were done by direct infusion using a syringe pump 
(Harvard Apparatus, Holliston, MA, USA) in manual tune mode whereby ion path 
settings were determined using the compound optimization algorithm of the 
AppliedBiosystems/MDS Analyst 1.5 software. Three of the most ten intensive MRM 
(Multiple reaction monitoring) transitions for each analyte were selected and 
summarized to one final method using the scheduled MRM algorithm which allowed the 
inclusion of three MRM transition (one quantifier and two qualifier ions) for each AA. 
Ion source parameters were optimized by FIA for the lower abundance compounds 
(curtain gas: 30 psi; collision gas: 5 psi; Nebulizer current: 2 µA, temperature: 400 ◦C, 
Nebulizer gas: 50 psi; desolvation gas: 80 psi; interface heater: on).  
 
2.2.6 Method validation 
Method development requires a precise validation using tests for sensitivity, linearity, 
precision and accuracy, matrix effects and stability. We validated the procedure 
according to selected guidelines (FDA, Bioanalytical Method Validation 2001; ICH, 
Validation of Analytical Procedures Q2 (R1) 2005; CDER, Validation of 
Chromatographic Methods 1994). 
For selectivity testing, 2 plasma samples and 2 serum samples were analyzed by using 
MRM-mode. In addition, 3 blanks and 3 concentration levels of aqueous standards 
were needed to compare the rate of interferences in chromatograms of samples, 
blanks and standards. The process was done using one quantifier ion (product ion 
which is the most abundant fragment of one molecule) and two qualifier ions (product 
ion of two alternative fragments of the same molecule). Qualifier ion ratio is calculated 
as the ratio of the signal intensities of quantifier to qualifier. This ratio can indicate 
possible co-eluting interferences (23). Furthermore, more than 700 samples in a clinical 
trial were measured and ratios of quantifier- and qualifier ions were calculated. 
Seven standard samples, each sample prepared three times, were used for calculating 
calibration linearity (r) of the calibration curve. Accuracy is the quality to being near to 
the true value. Therefore plasma control samples (level I and II, Recipe) were 
measured six times with our method. Accuracy was determined by comparison of the 
calculated concentrations with the set values from the manufacturer. Furthermore, we 
participated in a collaborative study (Ringversuch) to determine the accuracy of our 
study. This study is a method of quality assurance for measurement processes. 
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Basically identical samples were examined by different laboratories. Comparison of the 
results allows conclusions about the accuracy and quality for measurements of the 
participating institutes. Therefore, two different plasma samples were prepared and 
analyzed several times.  
Precision is divided into three parts: repeatability, interday and intraday precision. 
Injection repeatability was determined by injecting a plasma/serum sample ten times 
each. To evaluate intraday precision, one sample is prepared six times using same 
conditions by the same technician at the same day. For interday precision, one sample 
(serum and plasma) is prepared at six different days. 
Limit of detection (LOD) is the lowest value of analytes in a sample that can be 
detected but not quantified. The signal to noise ratio (S/N) should be > 3 (25). Lower 
limit of quantification (LLOQ) is the lowest concentration of analytes in a sample that 
can be detected and quantified. The determination of LLOQ requires a precision of 
20% CV and ± 20 % for accuracy bias (25). 
Another important part in method validation is the determination of matrix effects in 
terms of ion suppression (26). Therefore we tested for ion suppression using a 
permanent flow (100 µL/min) of a standard solution which was delivered by a infusion 
pump and combined via T-piece union with the eluent flow of a HPLC separation of a 
plasma sample (27). Figure 6 shows the construction and the determination of one 
selected amino acid.  
 
Figure 6: Test for ion suppression exemplified with alanine butyl ester. Derivatized Ala was added 
at a constant rate (c = 100 M) to the mobile phase via a flow splitter. Simultaneously, a plasma 
sample was injected and separated by HPLC. Ion suppression is discernible of the continuous AA 
standard signal at the beginning of the chromatogram. 
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The sample solution stability was determined because samples will be in solution for 
hours in the laboratory environment (cooled autosampler at 10° C) before the last 
sample injection is completed. After analyzing 111 samples within 48 hours, the first 
blood plasma was injected six more times. All plasma samples were quantitated and 
the coefficient of variation and the recovery were defined and compared. 
 
2.3 Results 
2.3.1 Efficient chromatography of 22 amino acids combining derivatization and 
ion-pairng 
Requirement for exact quantification of all AA is high resolution chromatographic 
separation. Because of the zwitterionic character the negatively chargeable carboxyl 
group can be protected by derivatization. Thus, the retention time of the peaks is 
changing but the sensitivity can be increased. The positive charged amino group is 
bounded by the anionic ion pair reagent (Heptafluorobutyric acid, HFBA). This leads to 
an amplified interaction with the stationary phase, analytes were retarded in a different 
way and chromatographic resolution and peak shapes are improved. Combining 
derivatization and ion-pair chromatography, our method enables us to quantify all 
proteinogenic AA, citrulline and ornithine within a total analyzing time of 22 min using a 
standard C18 reversed phase column. Figure 7 shows 22 extracted ion chromatograms 
of a plasma sample. Except for leucine/isoleucine and glutamine/lysine, each analyte 
shows its own MRM transition. The optimization of Gln and Lys showed very similar 
fragmentation patterns of the target ion m/z = 203 despite having a different chemical 
structure. Chromatographic baseline separation allowed their precise quantification. 
Besides Gln and Lys, also Leu and Ile had the same MRM mass transitions because of 
their isomeric chemical structure and identical molar mass. Both were baseline 
separated and could be quantified reliably. Over time, seven non proteinogenic AA 
have been added to the method: anserine (Ans), carnosine (Car), cystathionine 
(Cysta), hydroxylysine (HLys), hydroxyproline (HPro), methylhistidine (MHis) and 
sarcosine (Sar). 
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Figure 7: Extracted ions of 22 amino acid butyl esters. Extracted ion chromatogram of a plasma 
sample illustrating 22 AA. 
 
2.3.2 Sensitivity improvement for minimization of sample volume 
Derivatization of the negatively chargeable carboxyl group during butylester formation 
simplifies the protonation behavior by leaving only positively chargeable groups. 
Modification of the elution solvents with 0.5 mmol/L HFBA results in a quite acidic pH 
value of pH 1.5 – 2.0. Chromatographic retention in this setting is both enhanced by 
increased lipophilicity of butylesters as well as by ion-paring of HFBA with positively 
charged moieties. In addition, ionization efficiency is enhanced by favoring the 
positively charged state in acidic solution as well as by promoting the location of 
lipophilic butylesters to the droplet surface during electrospray desolvation. Butylation 
and ion-pair chromatography improved peak shape, selectivity and sensitivity. 
Therefore a sample volume of only 10 µL is adequate for accurate quantification. 
 
2.3.3 Sample clean up and assessment of ion suppression 
Sample clean up is important to precipitate interferences like proteins or phospholipids. 
Inadequate sample preparation of biological samples leads to matrix effects in terms of 
ion suppression. For a sufficient protein precipitation we added HCL to the precipitation 
reagents (consists of a mixture of methanol, IS and water). Further, sample 
preparations like derivatization with butanolic HCL at 60°C leads to degradation of 
phospholipids. Using post-column infusion system we assessed the ion suppression in 
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biological matrices. According to Taylor et al. a standard AA solution was added at a 
constant rate (c = 100µM, flow = 12µl/min) to the mobile phase via a flow splitter (27). 
At the same time a plasma sample was injected and analyzed (Figure 6). MRM 
transitions of phospholipids commonly encountered in plasma samples were monitored 
in addition (m/z = 758.6->184 or 786.6->184), but not detected. Figure 6 identified ion 
suppression within the first 2 min of the chromatogram.   
 
2.3.4 Concept of qualifier ions 
Typical performance testing and quality control protocols are based on analysis of 
periodic calibration check and/or reference samples or synthetic mixes. However, this 
cannot confirm the actual and real value of an unknown sample. A technique that can 
determine the quality of analytical results for each analyte is achieved by using qualifier 
ion monitoring as a fast and specific quality check. The advantage of this concept lies 
in monitoring the coelution-free, unbiased quantification in every single sample. Our 
method applies this concept to one of the first for bioanalytical LC-MS/MS for 
endogenous and small samples. Especially amino acid butyl esters are well suited for 
the qualifier ion monitoring. The optimization of Q1 and Q3 masses established at least 
2 MRM transitions for one analyte. The MRM transitions with the highest intensity were 
used for quantification, second and/or third transition were used as qualifier ions. 
Harder et al. show the MRM transitions of all analytes and internal standards (23). Due 
to butylation small molecules like alanine and glycine confirm a second MRM transition. 
Without butylation only one transition exists.  
 
2.3.5 Validation 
Selectivity testing was done without ‘Scheduled MRM’ mode and all MRM transitions 
were monitored during the entire analyzing time. Asp, Cit and Pro showed several 
peaks in the chromatogram. Using labeled internal standards and qualifier ion 
monitoring, all analyte-peaks were correctly assigned and coelution-peaks were 
excluded. Analyzing Pro standards and samples, two peaks were detected but only 
one peak showed the quantifier ion (m/z = 172 → 70) and both qualifier ions (m/z = 172 
→ 116 and m/z = 172 → 57) with their correct ratio. The unknown compound did not 
include m/z = 172 → 70 and showed a different retention time. An unknown compound 
is also observed in Cit. In EDTA plasma two peaks for Asp were detected but in serum 
samples only one peak was observed. The unknown compound was also noted in 
EDTA blanks (Figure 7+8).  
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Figure 8: Peak verification of aspartic acid in serum and EDTA plasma. Chromatogram of serum 
and EDTA-plasma illustrating the selectivity of the MRM transitions for aspartic acid: (a) extracted 
ion chromatogram of three MRMs for Asp in serum; (b) relative intensity (%) MRM spectrum for 
Asp of one quantifier ion and two qualifier ions (MRM fingerprint) in serum; (c) distribution of 
normalized qualifier ion ratio of Asp determined in 81 plasma samples; (d) extracted ion 
chromatogram of three MRMs 
 
For linearity an accurate calibration is prepared combining different matrices, 5 
aqueous standards and 3 matrix samples with and without spiking. By adding 0.1 N 
HCL to the precipitation reagents, reference factors of aqueous standards and matrix 
samples were equal. Calibration curves of all 22 AA were fitted by weighted (1/x) linear 
regression. Calibration linearity (r) of an eight point calibration curve were greater than 
0.992 (Table 6).  
Accuracy of our method was determined using two reference plasma samples. These 
available lyophilized plasma samples (ClinChek® Plasma Control,Lyophilized, Recipe, 
Munich, Germany) are a common choice to test internal quality assurance in clinical 
chemical laboratories. The manufacturer specified 21 AA values (except cystine) with a 
confidence interval of ± 20%. The accuracy of the control samples compared to the set 
values were within 82 – 118 % for level I and 96 – 117 % for level II (Table 6). 
Furthermore, we successfully participated in a collaborative ring trial to verify accuracy 
of our method.   
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Table 6: Validation results of all AA 
 Linearity Precision Accuracy LLOQ 
AA calibration 
linearity 
 (r) 
injection 
repeatability 
 [CV%] 
intraday 
precision 
 [CV%] 
interday 
precision 
[CV%] 
plasma 
Control 
 1 [%] 
plasma 
control 
 2 [%] 
LLOQ 
[µM] 
  
injection 
repeatability  
at LLOQ [%] 
Ala 0.993 1.6 3.3 3.7 97.3 102.8 1 2.9 
Arg 0.992 2.7 6.2 5.3 106.8 97.7 1 4.9 
Asn 0.995 1.1 5.5 7.1 101.0 98.4 1 5.2 
Asp 0.996 3.3 2.8 7.2 95.9 104.1 1 4.0 
Cit 0.994 2.3 5.2 10.2 105.2 98.2 1 12.3 
Gln 0.993 1.8 5.1 6.5 107.0 96.0 1 5.5 
Glu 0.996 2.1 5.9 10.2 95.1 105.6 1 7.3 
Gly 0.992 2.0 3.8 5.9 97.7 100.9 1 6.6 
His 0.993 3.2 2.6 10.4 99.4 98.5 1 6.3 
Ile 0.997 2.5 5.4 5.9 99.5 101.6 1 9.3 
Leu 0.997 2.1 4.0 4.8 99.3 99.3 1 4.8 
Lys 0.994 3.1 7.3 10.8 100.5 100.9 1 4.6 
Met 0.997 2.7 3.2 6.1 111.2 105.6 1 2.3 
Orn 0.994 3.4 10.1 5.7 106.9 96.1 1 8.1 
Phe 0.996 2.4 3.7 7.1 101.1 99.1 1 2.8 
Pro 0.993 3.0 8.4 6.1 103.5 96.5 1 4.4 
Trp 0.991 3.7 8.6 8.0 117.7 103.7 1 5.7 
Ser 0.995 2.4 4.3 6.1 99.6 98.9 1 9.6 
Thr 0.995 2.7 6.8 8.9 82.0 117.4 1 6.0 
Tyr 0.996 1.2 4.3 5.9 102.2 97.6 1 1.9 
Val 0.995 3.2 4.3 3.1 98.8 100.2 1 7.7 
Cys 0.993 4.8 8.3 10.6 N/A N/A 1 5.2 
 
For precision, injection repeatability, intraday and interday precision were performed. 
Injection repeatability of 10 consecutive samples was shown in table 6 and average 
injection repeatability was 2.6% (CV). Intraday precision of all analytes was in the 
range of 2.6 – 10.1% (CV). Analytes with low concentration (ornithine, CV 10.1%) show 
greater CVs as highly concentrated analytes (alanine, CV 3.3%). Interday precision of 
all AA was in the range of 3.1 – 10.8% (CV).  
 
The lower limit of quantification (LLOQ), with acceptance criteria of 20% CV for 
precision and ±20% for accuracy bias (25), of all AA analyzed was about 1 µmol/L. 
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Stability test was monitored for seven days. After seven days the recovery of all 
analytes was in the range of 94 -102 %, expect for aspartic acid (84%), cystine (74%), 
and ornithine (112%).  
 
 
2.4 Discussion 
2.4.1 Efficient chromatography combining derivatization and ion-pairing 
Due to the instability of Asn, Cys, Gln and Trp, only a few published methods allow the 
detailed analysis of all proteinogenic AA (24). Many procedures do not fully cover all 
analytes (28, 29). A major problem for detecting a huge spectrum of analytes is the 
insufficient peak sharpness of polar analytes like Asn, Cit, Gln (17, 18). Compared to 
our method, the commercial ITRAQ system for quantification of derivatives AA 
analyses 44 AA but is less sensitive and the required reagents are toxic and expensive. 
Using ITRAQ peak sharpness of Asn and Ser is not optimal either (19). In comparison, 
our method presents sharp peaks for all 22 measured analytes and efficient separation 
of the combined derivatization with ion-pair chromatography. The proposed method 
delivers high resolution chromatographic separation on standard C18 reversed-phase 
column which is extremely stable for thousands of samples. Because of a very 
favorable retention behavior, a separation within 16.5 min is possible using a modern 
HPLC technology. Improved chromatographic retention of polar AA allows for switching 
the beginning of the chromatogram to waste to reduce contamination of the mass 
spectrometers ion source. The flexible use of two ion sources (APCI, atmospheric 
pressure chemical ionization and ESI, electrospray ionization) provides a further 
advantage. Normally we used APCI because background signals and matrix effects of 
APCI have been reported to be often lower than with ESI (26). A minor drawback of 
derivatization with butanolic HCL is the formation of HCL gas during evaporation which 
may cause corrosion. Metallic parts of the evaporator device can be protected from rust 
by covering with adhesive film. 
 
2.4.2 Sensitivity improvement for minimization of sample volume 
By improving the sensitivity, a sample volume of 10 µL is used. Other procedures use 
considerably more sample volume (100 µL) (18, 28). The fact that the developed 
method requires only 10 µL of plasma or serum renders it well suitable for clinical 
studies. Especially in newborns or infants, sample collection is extremely difficult due to 
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limited sample volume. For the newborn screening laboratory, the new method may be 
suited as a second-tier analysis to reconfirm results from direct infusion analysis.  
 
2.4.3 Sample cleanup and assessment of ion suppression 
The addition of HCL (final concentration 0.1N) to the precipitation reagents (including, 
methanol, IS and water) enhanced protein elimination. Organic deproteination in 
methanol has been commonly used in previous publications (18, 28).  Also 
phospholipids, which are known as a major source of ion suppression in biological 
matrices, can be inactivated using derivatization at 60°C. The ion suppression test 
showed a decrease of basal intensity in the first two min of chromatogram. Therefore 
ion suppression is negligible because the first peak eluted after 4 min. The absence of 
ion suppression was also proved by the construction of one linear calibration curve 
mixing aqueous standards and matrix samples. A higher risk for ion suppression 
provides methods with faster gradients, early eluting peaks and less comprehensive 
sample clean up (17, 21, 30). 
 
2.4.4 Concept of qualifier ions 
Amino acid butyl esters confirmed high-intensity useful CID fragmentation patterns 
ideally suited for qualifier ion monitoring, since multiple product ions from 
complementary parts of the AA molecule were observed. Their intensity relative to the 
most abundant product was high enough to allow accurate calculation of qualifier ion 
ratio. Other derivatization processes often exhibit the loss of the derivatization group 
which makes this approach not well suited for qualifier ion monitoring. Dansyl chloride, 
another common derivatization reagent, produces a CID spectrum with uniform and 
unspecific fragments. The AA derivates are unstable and the fragmentation preferred 
the development of product ion 171 m/z (31). In our method, we use a number of 
fragments from CID but the common neutral loss 102 m/z appeared for 12 from 22 AA 
and is therefore used for quantification. Second and third transitions were used as 
qualifier ions depending on their intensity. 
 
2.4.5 Validation 
Based on the qualifier ion concept, interferences e.g. in Asp, Cit and Pro can be 
detected reliably and rapidly within one analytical procedure. The typical fingerprint for 
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Asp in EDTA plasma is completely different to the unknown interfering compound. The 
interference has not only been identified in EDTA plasma, also in EDTA blank. A 
possible explanation of this finding may be that EDTA is degraded during derivatization 
and esterified to form an isomer of aspartic acid butyl ester. The impurity shares two of 
three transitions with aspartic acid but can clearly be separated by absence of the third 
transition. Unknown compounds in Cit and Pro cannot be explained but separation of 
analyte and impurity was obvious and clear.  
Calibration linearity for all analytes was greater than 0.992 using eight points from 
different matrices.  The more calibration points from different matrices were used, the 
more precise was the calibration curve.  
Mean values for accuracy should be within ± 20% of the target values. Our method 
fulfilled the specified values for all analytes of all measured samples.  
Intraday and interday precision for all analytes was less than 11% and comparable to 
other methods (32).  
The LLOQ, with acceptance criteria of 20% CV for precision and ±20% for accuracy 
bias of all AA analyzed was about 1 µmol/L. Langrock et al have reported quantification 
limits of above 10 µM and Booger et al have reported similar values of LLOQ but using 
100 µL of sample volume. Our methods required a sample volume of only 10 µL with a 
LLOQ of 1µmol/L.  
Standard sample solutions were stable over seven days. Application of 14 stable 
isotopes justified the sample solution stability. Recovery of all compounds shows a 
variety of 94–102%, except for Cys (74%), Asp (84%) and Orn (112%). Cys is well 
known to be unstable. Low abundance AA like aspartic acid (normal concentration is 
about 20 µM) and ornithine (about 45 µM) exhibited higher variation. Therefore it is 
recommended to measure the samples as soon as possible.  
 
 
2.5 Conclusion 
Ion pair chromatography and derivatization to butyl esters have been combined to a 
new methodology for determination of plasma AA by LC–MS/MS. Several published 
methods are often less sensitive (17, 18). The developed method requires only 10 µL 
of sample volume, while other previously proposed methods used 100 µL of plasma 
(18, 28). The very small sample volume needed enables studies in infants, as well as 
the use of capillary (fingerstick) sample. Within 36 hours, 96 samples can be 
measured. Thus, our method is suitable for clinical trials with large number of samples.  
All proteinogenic AA, Cit and Orn can be measured in the same run with baseline 
chromatographic separation of Leu and Ile. Over time, seven non proteinogenic AA 
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have been added to the method: Ans, Car, Cysta, HLys, HPro, MHis and Sar. In 
comparison, existing methods often did not fully cover all proteinogenic AA (28, 29) or 
exhibited problems with appropriate chromatographic separation (insufficient peak 
sharpness, early eluting peaks) (17, 18). Further advantage of the new method is the 
modified sample preparation using HCl in methanol which results in markedly improved 
sample cleanup. Improved sample preparation enabled us to avoid ion suppression 
bias, which was proved by equal detector response of matrix-free calibrators and 
serum/plasma samples. Other published methods with less efficient sample cleanup 
and too short retention of early eluting analytes risked significant ion suppression (17, 
21, 30).  The proposed protocol is one of the first introducing the concept of qualifier 
ion monitoring to quantitative analysis of endogenous metabolites. Using this approach, 
we have shown that the well-known selectivity problem of small molecule bioanalytical 
mass spectrometry can be addressed in automated highthroughput analysis, ensuring 
unbiased quantitation of every single sample. Short run time and low costs per sample 
allow for analysis of large sample numbers, e.g. from epidemiological studies. 
  
APPLICATION IN CLINICAL RESEARCH 
30 
 
3 Amino acid profiles in formula-fed and breastfed infants 
from a randomized clinical trial 
3.1 Background 
Obesity is a more and more common problem in our world. Especially in industrialized 
countries, obesity is dramatically increasing due to less physical work and an 
oversupply of food. Over-nutrition is not the only major cause, also physical inactivity, 
genetic factors, eating disorders, metabolic disorders or food intolerance contribute to 
the pathology of obesity. In modern times, while children prefer to watch television and 
play computer games, advertisements for sweets, soft drinks, alcohol and fast food 
support causes for obesity. Within recent years a lot of work was done to find further 
reasons for the increasing incidence of obesity.  
Major problems of obesity are the consequence for health and economy. Obesity is 
strongly linked to adult disease like Type II diabetes, metabolic syndrome and 
cardiovascular diseases syndrome (14, 33-36). Bray et al. claimed obesity as a 
chronic, relapsing, neurochemical disease (37). Increasing obesity also results in the 
appearance of heart disease, hypertension and cancer (38) and has large implications 
for healthcare costs. In times of abundance, more and more people get obese and for 
many researchers it is a challenge to unravel the mechanism and the causes of 
obesity. Therefore, it is very important to understand causes of obesity. Recent studies 
in humans have suggested that there may be an association between rapid weight gain 
in infants and the later risk of obesity (39). A positive association of protein intake and 
early growth was observed by Stunkard and co-workers (40). He compared children of 
obese mothers, which have a high risk for overweight, with infants of lean mothers 
during the first 2 years of life. He proposes that growth and development of infants 
dependent on energy intake (40). In other studies, no effect of infant formula on growth 
in the first 4 month was observed (41).  
Early programming, the process by which different factors act during early life, may 
have long-term consequences on health. For example, specific questions could be: 
How does the diet of the mother, of the newborn or of the child affect the risk of later 
obesity? What is the impact of parental education, ethnic origin or infant gender on 
later obesity? In the context of a large EU funded research project, early programming 
is applied in the CHOP European Childhood Obesity trial where protein intake in the 
first year of life is examined for rapid weight gain in early childhood (1). More than 1000 
healthy, formula-fed infants were randomly assigned to receive cow-milk–based and 
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follow-on formula with lower (LP) or higher protein (HP) contents for the first year. Both 
groups were compared to breast fed (BF) infants.  With our new developed method 
which is described above, we analyzed and quantified serum AA of HP-, LP- and BF 
group and compared AA profiles in the infants to predict diet induced weight gain or 
obesity. 
In some studies, protein intake is associated with insulin-like growth factor (IGF-1) (14, 
42). IGF is a hormone with 3 possible peptide ligands (IGF I, IGF II, Insulin) and is 
involved in the regulation of growth and development (43). AA, the building blocks of 
protein, act as stimulators of insulin secretion suggesting a possible relationship 
between AA and IGF. In the late seventies, Felig et al. already observed an increase of 
Ile, Leu, Val, Phe and Tyr in obese subjects (44). Exactly 40 years later; Newgard 
confirmed the results and showed that BCAA supports insulin resistance in obesity 
(14). Furthermore, the group of Newgard investigated the association of special AA 
with the mammalian target of rapamycin (mTOR) (14). mTOR is responsible for cell 
growth, cell proliferation, cell motility, cell survival, protein synthesis and transcription 
(45). mTOR complex 1 (mTORC1) activation promotes cell growth and cell 
proliferation. mTORC1 acts as metabolic sensor and is regulated by availability of AA, 
growth factors, energy store and oxygen (46). Especially, Arg, Gln and Leu are 
important for mTORC1 activation (47, 48). Recent findings of the activation of 
mTORC1 showed that Leucyl tRNA synthetase plays a crucial role in AA induced 
mTORC1 activation. A significant association with development of diabetes is observed 
for BCAA and aromatic AA (49). 
  
Three different types of milk were fed to the infants, breast milk and two formula milks 
with low and high protein categories (1). The hypothesis was raised that high protein 
intake in infants can affect higher BCAA concentrations and leads to faster growth, 
elevated adipose tissue and elevated risk of later obesity. We investigated the effect of 
milk intake on the serum AA concentration in infants. 
 
3.1.1 Study design and population 
The study was a double blind, randomized intervention trial. Infants were fed with cow 
milk based formula with either high protein or low protein levels within the first year of 
life. Formula feeding in each of these two groups was started with an infant formula 
preparation and was switched to follow-on formula after 4 months. 1757 healthy 
newborns, born between October 2002 and July 2004, participated in the study and 
were recruited in 5 countries (Belgium, Germany, Italy, Poland and Spain). Newborns 
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of mothers with hormonal, metabolic diseases and drug addiction during pregnancy 
were excluded from the study. During the first eight weeks after birth, all infants were 
breastfed. Formula-fed infants were totally formula-fed after eight weeks up to the fifth 
month of age and breastfed infants had to be breastfed up to three months of age. 
Standard formulas were replaced by follow-up formula (from 4th month of age). 
Standard formula contained lower cow milk protein levels compared to follow-up 
formula but had an identical energy density. Differences in protein content were 
balanced by fat content. Details of formula nutrition and study population were reported 
by Koletzko et al. 2009 (1). Of 1757 healthy newborn recruited at birth, 1138 newborn 
were formula fed and 619 were breastfed. The group of formula fed infants was divided 
by protein intake level, low protein diet contains 1.8 g and 2.2 g protein/100kcal protein 
and high protein diet comprises 2.9 and 4.4 g protein/100kcal.  Eight European study 
centers (Reus, Spain; Tarragona, Spain; Warsaw, Poland; Brussels, Belgium; Liege, 
Belgium; Milan, Italy; Nuremberg, Germany and Munich, Germany) collected serum 
samples at 6 month after birth of 726 infants. Amino acid analysis was performed from 
275 low protein infant samples, 277 high protein infant samples and compared to 174 
breastfed infant samples (Figure 9). Longitudinal follow up was done for 
anthropometry, nutrition, neuropsychology and sample collection. 
 
Figure 9: Flow chart of the CHOP study subjects and numbers of group classification 
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3.1.2 Amino acid analysis 
At the age of sixth months, venous blood samples were taken and serum was stored at 
-70°C. 726 samples were transported on dry ice to Germany, Dr. von Hauner Childrens 
Hospital for AA analysis. Determination of AA was performed by HPLC (Agilent, 1100) 
coupled with mass spectrometric detection (Applied Biosystems, API 2000). Equipment 
for AA analysis is described in detail in chapter 2.2.1. A detailed description of sample 
preparation is given in chapter 2.2.5. 10 µL of plasma is added to a mixture of 
methanol, internal standard and HCL. After protein precipitation and centrifugation, a 
supernatant of 200 µL is dryed under nitrogen. For derivatization, 100 µL butanolic 
HCL is added and incubated for 15 min at 60°C. After evaporation, 100 µL mobile 
phase is added and 10 µL of sample is injected into HPLC.  
 
3.1.3 Sample definition for clinical trials in a 96 well plate 
In the morning before sample preparation, 81 samples were thawed and registered in a 
sample registration template. This template was developed by Wolfgang Peissner and 
is suitable for automatically batch writing for 81 unknown samples and standard 
calibrators. For clinical studies of more than hundred samples, it is advisable to use 96 
well plate samples due to the total high throughput measurement of 81 unknown 
samples in very short time. Figure 10 shows the arrangement of samples, standards, 
matrix and QC-samples and blank.  
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Figure 10: Arrangement of a 96 well plate for standards and sample. Well 1-81 is used for unknown 
samples (brown squares), well 82-89 is used for standard samples (blue squares), well 90-95 is 
used for QC-samples (green squares) and well 96 is used for the blank 
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3.1.4 Statistical analysis 
Statistical analyses were performed with Statistica (Version 10) (StatSoft GmbH, 
Hamburg, Germany) and medians (25 th ,50th ,75 th percentile) were calculated with 
Microsoft Office Excel 2007.  
 
3.2 Results 
3.2.1 Amino acid concentration in serum  
Measuring AA concentration in infant serum was finished for all proteinogenic AA 
besides cystine. Cystine is known as an unstable compound and only fresh aliquots 
with short storage time can be reliably qualified. Additionally, Cit and Orn were 
analyzed. Comparison of 21 AA levels indicated a clear difference between groups of 
high and low protein. All AA concentrations of BF, LP and HP are shown in table 7. P-
values were calculated between LP and HP group.  In general, LP and BF group differ 
only marginally and are roughly comparable. Differences were observed between the 
LP and the HP groups.  All essential AA were significantly elevated in HP. Especially 
the BCAA (Leu, Ile and Val) showed differences between LP and HP. In contrast, most 
non-essential AA (Ala, Arg, Asn, Asp, Cit, Gln, Glu, His, Orn, Ser) were not affected by 
different protein intake. For Gln and Glu, we observed a tendency towards higher levels 
in BF compared to LP and HP. Gln, Glu and Gly showed a slight elevation in LP group. 
Non-essential AA, Gly, Pro and Tyr also differed significantly between LP and HP 
group. A representation of the results is revealed as box plots in figure 11. Based on 
the plots, the influence of protein intake on concentration of the essential AA is clearly 
depicted. In the box plot of Phe, we observed an outlier in HP group with 502 µmol/L. 
In physiological concentrations, the average of Phe is around 100 µmol/L. In figure 12, 
the outlier of Phe is first included and marked with an arrow and secondly excluded.  
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Table 7: AA concentration of infants in BF-, LP-, HP-group. Blood samples were collected 6 month 
after birth. All results presented as medians (25th, 75th percentile). P values, between LP and HP, 
were calculated with the use of independent t-tests. 
AS BF LP HP P value 
 n=174 n=275 n=277  
Ile 70 (59, 91) 75 (63, 88) 101 (80, 128) 0.000000 
Leu 132 (112, 170) 143 (123, 173) 201 (160, 253) 0.000000 
Lys 190 (161, 232) 195 (162, 234) 230 (186, 270) 0.000000 
Phe 81 (68, 101) 96 (78, 111) 110 (93, 131) 0.000000 
Trp 64 (56, 74) 60 (52, 72) 74 (60, 87) 0.000000 
Tyr 84 (69, 103) 101 (85, 126) 125 (94, 154) 0.000000 
Val 213 (181, 274) 256 (220, 299) 367 (291, 458) 0.000000 
Pro 284 (242, 364) 296 (243, 368) 339 (267, 446) 0.000002 
Thr 144 (123, 181) 145 (125, 178) 164 (138, 205) 0.000002 
Met 28 (23, 35) 35 (28, 41) 38 (30, 49) 0.000005 
Gly 287 (236, 334) 334 (270, 409) 296 (244, 361) 0.000042 
Asn 50 (40, 63) 50 (40, 62) 56 (44, 68) 0.001704 
Cit 25 (19, 34) 30 (25, 39) 34 (28, 39) 0.003912 
Asp 44 (34, 55) 42 (34, 52) 45 (37,57) 0.016384 
Gln 505 (420, 612) 484 (384, 588) 441 (365, 551) 0.018738 
His 101 (89, 123) 108 (93, 128) 113 (98, 132) 0.051140 
Glu 306 (256, 403) 273 (225, 348) 263 (211, 327) 0.075365 
Ala 467 (402, 567) 476 (385, 601) 466 (387, 551) 0.167310 
Ser 233 (203, 270) 214 (183, 252) 214 (187, 259) 0.704893 
Orn 111 (84, 143) 105 (85, 138) 104 (83, 137) 0.890628 
Arg 174 (142, 218) 174 (141, 222) 173 (140, 213) 0.997504 
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Figure 9: Box plots of serum AA concentrations in formula-fed and breastfed infants at 6 mo of 
age. 
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Figure 10: Box plots of Phe concentrations in formula-fed and breastfed infants at 6 mo of age 
(with outlier, marked with a black arrow, and without outlier) 
 
3.3 Discussion 
We found that HP intake in formula affected serum AA concentrations which markedly 
differed from the breastfed infants. HP group show increased serum AA levels 
especially for the essential AA Ile, Leu and Val. Our findings confirm the results of 
studies with Socha et al. 2011 (50). The group of Socha analyzed the AA from the 
same study using amino acid analyzer with showing the same major results.  Further 
analyses are necessary for detailed information about later risk of weight gain or 
obesity. High values of essentials AA in HP group in early infancy might be a risk for 
weight gain in early infancy (50). To reflect on reasons for infancy weight gain feasible 
explanation can be given in detail in further chapter.   
 
3.3.1 Transport of AA 
AA are supplied as proteins to the diet. Digestion of these proteins starts in stomach 
but happens mainly in the small intestine to AA. The small intestine is the absorption 
organ for AA coming from dietary protein and the first pass for AA to circulation. 
Influenced by protein hydrolysis and microflora in the intestine, AA pass through active 
transport to the portal vein blood and free AA enter liver cells. In the long run, AA reach 
circulation (8). Except Ile, Leu and Val, all AA are degraded in the liver for systematic 
circulation. The BCAA (Ile, Leu and Val) contribute to different metabolic processes 
such as acting as substrates for protein synthesis, precursors for Ala and Gln 
synthesis, as modulator of muscle protein synthesis and as central nervous system 
control of food intake. Due to their important role in metabolism, it is interesting that 
BCAA are not degraded in the liver (51). Liver is not suitable for degradation of BCAA 
due to lack of the responsible aminotransferase, which is involved in the first 
degradation step of BCAA (51). BCAA are preferentially oxidized in muscle, fat, kidney 
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and brain tissue (8). The group of Herman depicted an increased oxidation rate of 
BCAA in adipose tissue from normal mice compared to skeletal muscle (52).  
AA transport across the plasma membrane is mediated by AA transport systems (53). 
The literature presents different AA transport systems where AA can enter circulation. 
At least seven transport systems from blood to somatic cells are known, but a lot more 
are assumed (Table 8) (8). 
Table 8: Transport systems of AA (this table was constructed after Löffler et al. (8)) 
Amino acid transport system  Amino acids 
A Ala, Gly, Ser, Pro, Met 
ASCP Ala, Ser, Cys, Pro 
L Leu, Ile, Val, Phe, Tyr, Trp, Met 
Ly Lys, Arg, Orn, His 
Dicarboxylat Asp, Glu 
ß Taurin, ß-Ala 
N Gln, Asn, His 
 
Among these systems, the AA transport system L, an Na+ independent transport 
system,  is a major nutrient transport system responsible for the transport of neutral AA 
including several essential AA such as BCAA and aromatic AA (54). During HP intake 
we observed significantly higher serum values in Ile, Leu, Val, Phe, Tyr, Trp, Met, Gly 
and Lys. It is obvious that BCAA, aromatic AA and Met are transported by system L 
into circulation.  
For Gln we observed high serum concentrations in the lowest protein group (BF) and 
Gln behaved differently than other AA. Gln is the transporter unit for amino groups and 
tissue exhibits higher concentration of Gln. It is interesting that high protein intake leads 
to decreasing levels of Gln. It seems that an oversupply of protein, Gln values 
decreases.  
Non-essential AA are catabolized in the intestine and de novo synthesis is the major 
determining factor of systemic concentration. 
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3.3.2 Activation of mTOR by AA 
The mammalian target of rapamycin (mTOR) is an serine/threonine protein kinase and 
belongs to the phosphoinositide-3-kinase (PI3K) related kinase protein family (55). 
mTOR is a key component of two multi protein functional complexes, mTOR complex 1 
(mTORC1) and mTOR complex 2 (mTORC2). Each complex consists of different 
proteins, some are found in both subtypes and each complex provides diverse 
functions exclusively. mTORC1 activation supports many intra and extra cellular 
processes such as cell growth, cell proliferation and is regulated by growth factors, 
nutrients (especially availability of AA), oxygen and energy sensing signals. mTORC2 
subserves for cell processes such as survival and polarity of cells and cytoskeletal 
organization (46, 48). Moreover, an inappropriately high level of mTOR activity plays a 
central role in the development of several diseases including metabolic syndrome, 
cancer and diabetes (45, 56, 57). 
AA are necessary for activation of mTOR (58). The presence of AA, especially Leu and 
Glu, regulated mTORC1 (46). Leucine is included in protein synthesis steps and serves 
as regulator of protein synthesis. mTORC1 consists of mTOR, regulatory associated 
protein of mammalian target of rapamycin (Raptor), G protein b subunit-like protein 
(GbL), proline-rich Akt substrate of 40 kDa (PRAS40), and Deptor (58). For activation 
of mTORC1, AA are directly acting on Rheb. Rheb is identified as a gene that is rapidly 
induced in brain neurons (48). Activation of mTOR by AA is mediated by the Rag family 
including heterodimers RAGA or RAGB and RAGC or RAGD. Figure 13 shows a very 
simplified scheme of mTOR activation by AA or growth factors. These activators are 
two essential aspects for mTOR activation. Moreover, Leu and Gln are the most 
important AA for activation process. During a protein rich diet, Leucyl tRNA synthetase 
is involved in mTORC1 activation. The Rag anchored by ragulators (MP1, p14, p18) on 
the lysosome membrane. This membrane can activate Rheb which is activating 
mTORC1. Rheb activity is improved by TSC complex. If the activation of mTOR is 
caused by AA, a high protein intake could promote cell growth and therefore weight 
gain. Various authors support this hypothesis. Hoppe and coworkers analyzed 142 
Danish infants fed with high protein diet and seems that protein intake stimulate early 
growth (59). Further authors confirm weight gain in infants whose compared breastfed 
infants and formula fed infants (60-62). 
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Figure 11: Overview of mTORC1 activation by AA and growth factors (Different publications were 
used to illustrate a simplified representation of mTORC1 activation (46, 48, 58)) 
 
3.3.3 Activation of IGF-1 
Insulin like growth factor (IGF) is a complex protein with high resemblance to insulin. 
This complex molecule consists of two ligands (IGF-1 and IGF-2), four receptors (IGF-
1R-IGF-4R), six IGF binding proteins (IGFBP1-6) and the acid-label subunit (ALS) of 
the circulating IGFBP complex (63). IGF-1 and 2 consists of single chain peptides with 
7.5 kDa where IGF-1 is composed of 70 AA and IGF-2 consists of 67 AA. The IGF 
molecule showed four domains (A-D), domain A and B are equal to the A and B chains 
of insulin (42). IGF-1 displays a major role in growth and development as a function of 
disposable energy and essentials nutrients (e.g. AA) from body reserves and diet (64). 
Experimental studies have implicated IGF-1 blood concentration differs by changing 
the diet (especially protein intake). AA, in particular BCAA are closely linked to 
stimulation of insulin secretion. Furthermore, IGF axis is known to regulate early growth 
and affect adipose tissue (50). IGF concentration in LP and HP can provide information 
about stimulation of insulin secretion. In this study IGF parameters were not measured 
in my doctoral thesis but the publication of Socha et al. illustrate the measurement of 
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IGF-1, IGFBP2 and IGFBP3 in the same study. The group concludes that HP intake 
stimulates IGF axis and insulin release in infancy.  IGF-1 improves growth during the 
first 6 month of life (50). 
 
3.3.4 Effects of protein intake in formula-fed infants 
Protein intake in the first year of life may exert several effects. In addition to preferential 
uptake from BCAA into the muscle, increased BCAA concentrations result in activation 
of mTOR and IGF-1 (50, 58). On the one hand mTOR, activation supports many intra 
and extra cellular reactions such as cell growth, cell proliferation. On the other hand, 
Newgard supported the association to insulin resistance (14). AA are correlated to 
insulin release and insulin is known to increase cellular glucose uptake and inhibition of 
lipolysis. This metabolic alteration is linked with weight gain and the achieved body 
mass index. Rapid weight gain is a risk factor for development of overweight in later life 
(65, 66) and risk of obesity is also known from IGF-1 activation (50). In addition, an 
increased protein intake is associated with early puberty (67). High values of BCAA, 
Tyr and Phe correlates with diabetes and might be a predictor for future diabetes (49, 
68). In comparison with BF infants, high protein diets with higher concentrations of 
numerous AA especially BCAA observed increasing BCAA concentration in serum and 
could lead to a number of effects on later life (Figure 14).  
 
Figure 12: Effects of increased blood BCAA on human body (information has been assembled from 
several references and summarized in one figure (14, 46, 49, 50, 57, 65, 68-70)) 
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Different effects of increased blood BCAA concentrations are reported in several 
publications. Increased BCAA values leads to an enhanced activation of growth 
hormones like mTOR, IGF-1 and gluconeogenesis (14). mTOR activation is associated 
with insulin resistance (14) and increased IGF-1 values show a higher risk for obesity 
and diabetes (14, 49). The connection between the directly observed growth factor 
activation (mTOR, IGF-1) and the subsequent increase in risk of several diseases is 
not described in detail (71, 72). By reducing the protein content in infant formula, blood 
BCAA concentrations are lower and possible effects (such as listed in figure 14) maybe 
reduced. The same energy density with a reduced amount of protein (available in LP 
and BF) could show a reduced activation of growth hormones (mTOR, IGF-1). These 
results support the imprinting of feeding breast milk. This statement is supported by 
other authors by diminishing obesity trough lower protein intake in early infants (1). 
 
 
3.4 Conclusion 
With our novel method development, we quantified serum AA of HP-, LP- and BF 
group and compared AA profiles in the first year of life to predict diet induced weight 
gain or obesity. Results of formula-fed infants were evaluated with breast fed infants. 
This showed a significant difference in serum AA profiles such as BCAA, Gly, Lys, Met, 
Phe, Pro, Thr, Trp and Tyr. Essential AA were absorbed from diet and probably 
released into circulation via L-transport system. Non essential AA are mainly 
catabolized in the intestine and de novo synthesis is the major determining factor of 
systemic concentration. AA are necessary for activation of mTOR and IGF-1. By the 
presence of high AA concentration in HP group, mTOR can be activated resulting in 
cell growth and cell proliferation. However, diseases such as insulin resistance, 
diabetes, fat accumulation can be caused by increased protein intake. Based on the 
observations of potential risk, a reduced protein intake in early life and/or breast milk 
feeding infants could contribute to health. 
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4 Plasma Amino acids of CLA supplemented cows 
4.1 Background 
 
Conjugated linoleic acid (CLA) refers to a group of geometric and positional conjugated 
dienoic isomers produced during biological or industrial hydrogenation of linoleic acid 
[18:2(n-6), Δc9, c12] (73). The biologically important isomers are cis9,trans11-CLA and 
trans10,cis12- CLA. Cis9,trans11-CLA, as a so-called rumen acid, is mainly isomerized 
from linoleic acid in the rumen of ruminants during the microbial biohydrogenation by 
the rumen bacterium Butyrivibrio fibrisolvens (73). Trans10,cis12-CLA is also formed in 
the rumen by bacteria, but in lower concentrations. Therefore, milk and milk products, 
meat and meat products from ruminants and partially in hydrogenated vegetable oils 
contain CLA isomers. The total CLA content in milk is about 2-30 g/kg fat, while values 
in beef are differing between 3.1- 9.9 g/kg fat (74). In the rumens of sheep and cattle, 
microbial bioconversion mainly produces the cis9,trans11-CLA isomer, whereas dietary 
supplements and functional foods contain cis9,trans11-CLA and trans10,cis12-CLA 
isomers in approximately equal amounts (75).  
There is great interest in CLA and conjugated linolenic acid isomers because of their 
supposed health-promoting properties. This is surprising because most trans fatty 
acids in food are usually undesirable due to their formation in technical processing 
(heating, hardening). Nevertheless, CLA is becoming more popular since 1987 when 
Michael Pariza discovered this compound (73). CLA has been implicated to a lot of 
beneficial biological effects on human health. Supplementation of CLA for 4 weeks 
reduces body fat in human men with signs on metabolic syndroms (76), benefit effect 
on immune function was observed in 28 healthy human participants (77) and reduce of 
body fat was also observed in 62 obese children (78). Furthermore, CLA 
supplementation in humans is associated with reduction of cancer incidence in rats and 
mice, reduction of severity of atherosclerosis and enhancement of lean mass (79-81). 
According these effects, supplements of CLA are available for sale and manufacturer 
promote rapid weight gain.  
The conviction of beneficial CLA effect is also utilize in animal breeding. Benefits of 
CLA supplementation have been refuted by different working groups (82, 83). In 
contrast, the thesis of milk fat synthesis reduction is confirmed by several researchers 
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in cows (84) and goats (85). In the study of Lock milk yield, dry matter intake and 
protein content were not affected by treatment of CLA (85). 
During the last 15 years isomers of CLA has received considerable scientific interests 
after the demonstration of beneficial effects on cardiovascular and oncological 
diseases in laboratorial animals (86). According to position and configuration of the 
conjugated double bonds, various isomers of CLA with differing effects have been 
identified (87). Park et al. initially observed a decreasing effect on body fat in mice (88). 
Later studies reported that fat loss was stronger in growing than in mature animals 
(89). However, CLA may negatively affect insulin resistance and leptin concentration in 
mice (90). Terpstra et al. summarized CLA effects on insulin, leptin, glucose and 
plasma lipids in humans (91). Effects of milk composition or metabolic key parameters 
on CLA supplementation were also mentioned in cows (92, 93). Supplementation with 
CLA - in particular the t10, c12 CLA isomer - reduces milk fat and causes changes in 
fat metabolism of dairy cows. Lanna et al. discussed the effect of CLA supplementation 
on fatty acids (94). However, CLA effects on AA concentrations are generally unknown. 
In energy deficiency, as it occurs during early lactation in high producing dairy cows, 
the energy spared by CLA-induced milk fat depression might be repartitioned towards 
synthesis of milk protein. This could be reflected in different time courses of free AA 
during early lactation in plasma and milk. Therefore, CLA supplementation on amino 
acid profiles was investigated as, to our knowledge, this relationship was not 
investigated at this time. With our new developed method which is described in section 
2, we quantified AA of plasma and milk samples of dairy cows and compared AA 
profiles in CLA supplemented and non CLA supplemented cows. For example, specific 
questions could be:  Does CLA supplementation change AA concentration in dairy 
cows? Apart from the milk fat reduction there may be a change in AA concentrations. 
During lactation, gluconeogenesis could be influenced by CLA, whereby propionate 
from ruminal metabolism is the major substrate for generation of glucose (95). One 
further idea is to investigate whether CLA supplementation in cows takes another way 
to generate glucose. Because of transamination and deamination processes of AA, the 
carbon skeleton could be used for gluconeogenesis. Maybe CLA supplementation 
affects AA metabolism, which could result in changed glucose production.  
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4.2 Materials and Methods 
4.2.1 Animals and Treatment 
Twenty German Holstein cows (first lactation >9.000 kg milk in 305 d) were kept in a tie 
stall at Leibniz Institute for farm animal biology (FBN) and were fed a total mixed ratio 
(TMR) ad libitum based on grass and corn silage and had free access to water (Table 
9). They were randomly assigned to 2 groups three weeks (wk) prior to parturition. 
From 2 wk before to 9 wk after expected calving one group (CLA, n=10) was 
supplemented with 50 g/d Lutrell pure, (BASF, Ludwigshafen, Germany) containing 
11.8 g/100g trans-10 cis-12 linoleic acid. The control group (Ctrl, n=10) was 
supplemented with 50 g/d control fat (linoleic acid; cis-9 cis-12) preparation (BASF; 
Ludwigshafen, Germany).  
Table 9: Ingredients and chemical composition of diets 
Composition Diet 
g/kg dry matter 
Close-up1 Lactation2 
Corn silage 
335 315 
Grass silage 
255 165 
Wheat straw 
  80   20 
Grass hay 
  50   50 
Concentrate MLF 20003 
 320 
Concentrate Universal 18/34 
170  
Extracted rapeseed meal 
100   40 
Dryed beet pulp 
   80 
Minerals5,6 
  10   10 
Chemical composition 
  
Utilizable protein7 
140 165 
NEL
7 
  6.5   7.1 
ADF7 
220 160 
NDF7 
390 300 
 
1 Close-up diet was fed between 2 wk before until calving 
2 Lactation diet was fed after parturition. 
3 Concentrate MLF 2000 contained: 33% soya, 20% corn, 17% wheat gluten, 13% 
wheat, 8% rape seed expeller, 5% low sugar beet pulp chips, 2% Sodium hydrogen 
carbonate, 1.3% Calcium carbonat, 0.2% sodium chloride 
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4 Concentrate Universal 18/3 contained: 20-40% Cereals (triticale, rye, wheat, barley), 
< 25% rape seed expeller, malt germs, wheat gluten, wheat bran, peeled oat-bran, 
beet pulp chips, molasses, glycerol, minals, vitamins 
5 Minerals in close-up feeding contained: 14% Calcium, 12.5% sulphur, 12% chlorine, 
10 % magnesium, 2% phosphorus 
6 Minerals in lactation feeding contained: 92% crude ash , 8% phosphorus  6 % 
magnesium, 5% calcium   
7 German Society of Nutrition Physiology. 2001. 
 
4.2.2 Data recording, sample collection and analysis  
Cows were milked twice daily and dry mater intake (DMI) and milk yield were recorded 
daily, BW and milk composition were measured weekly. Feed analysis was performed 
according to Weender Standard Procedure (96) at the Agricultural Faculty of the 
University of Rostock and at the Landwirtschafliche Untersuchungs- und 
Forschungsanstalt, Rostock, Germany. Milk samples were analysed for fat, lactose, 
and protein in milk by the Landeskontrollverband für Leistungs- und Qualitätsprüfung 
Mecklenburg-Vorpommern e.V. (Güstrow, Germany). Energy corrected milk (ECM) and 
energy balance was calculated as described (97). Aliquot milk samples of wk 1, 2, 3, 4, 
6, 9 and 12 were collected.  
Furthermore blood samples were taken by venipunture in Li-heparinate monovettes 
(Sarstedt, Nümbrecht, Germany) 2 wk before expected calving and after delivery at wk 
1, 2, 3, 4, 6, 9 and 12. Samples were stored at -20°C until the analysis of free plasma 
AA. For the analysis of samples a new standard for external calibration was purchased 
(Fluka, amino acid standard, physiological) which includes more AA with a carboxyl 
group. We quantified twenty six AA (all proteinogenic AA plus Car, Cit, Cysta, HLys, 
HPro, MHis and Orn) by LC-MS/MS combining derivatization and ion-pair 
chromatography as described in detail in section 2.2.5.  
 
4.2.3  Statistical analysis 
Data were analyzed using the ANOVA (PROC MIXED) procedure of SAS with diet and 
lactation wk as fixed effect, and diet x time interaction. Plasma AA concentrations were 
adjusted for basal plasma AA values prior to CLA supplementation and parturition. 
Values are expressed as means ± SE. Pairwise Pearson correlation and scatter plots 
of all AA were created using Excel. Pearson correlation coefficients between plasma 
and milk AA concentrations within group and lactation wk were calculated. The 
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significance level was set at P < 0.05, and a trend was considered when 0.05 ≤ P ≤ 
0.10. 
 
 
4.3 Results 
4.3.1 Amino acid concentrations in plasma and milk 
Plasma AA concentrations from late pregnancy until to the twelfth wk after calving are 
shown in the Appendix table 1 for the CLA group and Appendix table 2 for the control 
group. The table shows the averaged absolute values of all measured free plasma AA 
with standard errors (SE). All concentrations were lying in the range between 0 µmol/L 
and 687 µmol/L. Cysta and HLys was detectable but determined concentrations were 
below lower limit of detection (LLOD). In contrast to Cysta and HLys, Gly showed the 
highest plasma concentration of all analytes (261 µmol/L – 687µmol/L). In general, the 
largest changes of AA concentrations occurred between the second wk before and the 
third wk after calving. Onwards, only slow increases or decreases were observed.  
Free milk AA concentrations behaved totally different from plasma AA. In milk, only Ala, 
Arg, Asn, Asp, Gly, Glu, HPro, Lys, Pro, Ser, Thr and Val could be reliably quantified 
with extremely high values for Asp and Glu. Concentrations of other free milk AA could 
not detected within the LLOQ of 1µM. Compared to plasma, concentrations of free Glu 
and Asp in milk were 11-fold and 5-fold increased, respectively. AA like Gly, HPro, 
MHis, Pro, Ser and Val decreased over time, while other AA did not change 
appreciably with advancing lactation.  
 
4.3.2 Correlation of plasma AA 
Table 10 shows selected pair-wise Pearson correlations of all plasma amino acid 
concentrations without consideration of the longitudinal gradient sorted by R-squared 
values in decreasing order. Especially Ile and Leu (figure 15A) and Ile and Val showed 
similar correlations with R-squared values of R² = 0.8600 and R² = 0.8068, 
respectively. Arg concentrations were positively related to Orn concentrations with R² = 
0.8030 (15B). Positive linear relations were also observed between Arg and Asp (R² = 
0.7167), Asp and Lys (R² = 0.6322), Thr and Lys (R² = 0.6879) and Phe and Tyr (R² = 
0.7406). The correlation between the pairs Asn/Asp (figure 15D) and Gln/Glu (figure 
15C) is completely different where Asn/Asp show a moderate positive correlation of 
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0.6193 but Gln/Glu only show a R-squared value of 0.3376. No significant correlation 
was observed between Asp and Glu (R² = 0.1158), Glu and Pro (R² = 0.0610), Ser and 
Trp (R² = 0.1658) and Thr and Gly (R² = 0.1006). Interestingly, positive linear relations 
between two AA with high R-squared values also show similar time courses trends. 
 
Table 10: Pairwise Pearson correlation of selected AA 
Amino acid Correlated Amino acid R-squared values 
Leu Val 0.8655 
Ile Leu 0.8600 
Ile Val 0.8068 
Arg Orn 0.8030 
Phe Tyr 0.7406 
Asp Arg 0.7167 
Thr Lys 0.6879 
Asp Thr 0.6660 
Asp Lys 0.6322 
Asn Asp 0.6193 
Asp Ile 0.5476 
Orn Pro 0.5280 
Cit Orn 0.5098 
Arg Cit 0.5091 
Asp Met 0.4810 
Ala Asp 0.4611 
Thr Ile 0.3836 
Gln Glu 0.3376 
Ile Trp 0.3248 
Gln Ser 0.2535 
Ser Trp 0.1658 
Asp Glu 0.1158 
Thr Gly 0.1006 
Glu Pro 0.0610 
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Figure 13: pair-wise metabolite scatter plot for selected AA pair concentrations in plasma 
measured with LC-MS/MS; A Ile/Leu pair, which are high correlated (0.8600, Pearson), B Arg/Orn 
pair, which are high correlated (0.8030, Pearson), C Gln/Glu pair, which are uncorrelated (0.3376, 
Pearson) and D Asn/Asp which are moderate correlated (0.6193, Pearson). 
 
4.3.3 Time courses of plasma AA 
Time courses of plasma AA were classified in 3 different groups. Figure 16 shows time 
courses of all AA. In the largest group of AA (Ala, Arg, Asp, Asn, Cit, His, Ile, Leu, Lys, 
Met, Orn, Pro, Thr, Trp, Tyr, Val), concentrations were decreasing shortly after calving 
and then up-regulated again approaching basal or higher values at the end of the 
observation period (all black marked AA in figure 16). In the second group (Gly, HPro, 
MHis and Ser) concentrations increased after delivery and then moved back to basal 
values (all green and orange marked AA in figure 16). Plasma concentrations of MHis 
peaked around wk 1 after calving and gradually decreased below starting values in the 
following weeks (highlighted in orange in figure 16). The last group of AA (Gln, Glu, 
Phe) was characterized by post-parturition decrease of plasma concentrations, which 
was sustained until wk 12 (all grey marked AA in figure 16).  
 In general, data points around delivery take extreme values. Concentrations of Arg, 
Orn, Thr, Trp, and Val were strongly reduced from ap to first wk pp and increased 
thereafter, mostly returning to ap levels in lactation wk 3-4. In contrast, Phe dropped 
from ap to first wk pp and remained at this level until wk 10. Some AA slowly increased 
to the ap level within twelve wk. A time effect of free milk AA concentrations is only 
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observed for Arg, Asp, Glu, Gly, HPro, Ser and Val with a significance value p=0.01. 
Plasma AA like Arg, Asn, Asp, Car, Gly, HLys, HPro, MHis, Orn, Thr, Trp and Val 
concentrations were affected by lactation wk (p≤0.05). None of the free AA differed 
significantly between the CLA group and the control group at any time point. 
The supplementation with CLA did not affected plasma concentrations of AA. It seems 
as if AA concentrations are higher in the control group compared to the CLA group. It is 
also interesting, that basal values in the control group are higher which is not significant 
and might be purely accidental. An intervention effect of free milk AA concentrations is 
not observed. 
 
Figure 14: Time courses profiling of mean plasma AA concentration with Standard Error from week 
-2 ap to wk 12 pp The x-axis represents 8 data points of time in weeks from -2 to 12 weeks and the 
y-axis the absolute mean plasma concentration of both groups (red line: CLA group; blue line: 
control group). Data are presented as mean ± SE 
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4.4 Discussion 
4.4.1 Correlation of AA pairs are dependent on equilibrium reaction 
Same functional groups show high relations between the corresponding AA. Especially 
Ile, Leu and Val (BCAA) are highly correlated in functional groups. One possible 
explanation for high correlations between the BCAA can be explained by close 
proximity of metabolic pathways and involved enzymes in equilibrium reactions that 
convert BCAA obviously directly in one and another with plasma levels changing in 
parallel. This statement is in agreement to the results of Camacho et al (98). This group 
explained the origin of correlation in the metabolic network. To their opinion, 
correlations dependent on equilibrium reaction, mass conservation, single enzymes 
and asymmetric control distribution (98). Arg concentrations correlated positively with 
Orn concentrations due to the conversion of Arg to Orn. Correlation between Arg and 
Cit (R² = 0.5091) and Orn and Cit (R² = 0.5098) is lesser but a positive tendency is 
observed.  Lys, Met, Thr and Ile are synthesized from Asp resulting in high correlation. 
Positive high correlation in AA metabolism is observed between Phe and Tyr where 
Phe is oxidized to Tyr. Hydrolysis from Asn to Asp shows a correlation of 0.6193 
(Figure 15D). The metabolic neighbor-pair Gln and Glu are less correlated where Asp 
and Glu are subjects to hydrolysis reactions due to aparaginase and glutaminase, 
respectively. Camacho et al confirmed the lesser correlation between Gln and Glu with 
the statement of a not necessarily correlation of neighbor metabolites. There are a lot 
of neighbor analytes pairs in the metabolic map, which have low correlation e.g. Gln 
and Glu. In summary we can explain some metabolic reactions by correlations. 
Measuring correlation can give information about the biological reactions between 
metabolites.  
 
4.4.2 Classification of time courses 
4.4.2.1 Stress and negative energy balance leads to decreased AA levels after 
delivery  
Figure 16 shows time courses of all plasma AA which were classified in 3 different 
groups.  In the largest group of AA (Ala, Arg, Asp, Asn, Cit, His, Ile, Leu, Lys, Met, Orn, 
Pro, Thr, Trp, Tyr, Val), concentrations were decreasing shortly after calving and then 
up-regulated again approaching basal or higher values at the end of the observation 
period. Low concentrations of AA might be explained by stress of delivery and negative 
energy balance. Meijer et al. determined the peripartal concentrations of 23 AA in 36 
dairy cows and observed very similar time curves (99). Compared to the group of 
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Meijer our results are more detailed due to more measured AA, the lesser variance and 
thus the more precise time courses. The author observed the rapid recovery of Lys, 
Thr, Trp, Tyr and the branched chain AA (BCAA). Furthermore, absolute plasma AA 
concentrations of Arg, Asp, Cit, Gln, His, Ile, Leu, Lys, Met, Phe, Orn, Ser, Thr, Trp, Tyr 
and Val were comparable, but for absolute AA concentrations of Ala, Asn, Glu, Gly, Pro 
and Trp results differ. This may be explained by breed, food intake, age or analytics. 
Furthermore, plasma Arg seems to be a marker for hypothalamic feed intake regulation 
in rats (100). Laeger 2012 observed an elevation of plasma arginine level after feed 
restriction in dairy cows (101). In our study plasma arginine is also increasing with. 
Thus, plasma arginine seems to be a less critical signal for feed regulation in cows. 
Plasma Lys did not show significant time dependence but a tendency to increase in 
later samples. Laeger explained that elevated Lys concentrations originate from protein 
breakdown in lactating cows (101).  
 
4.4.2.2 Increased MHis levels as a marker for muscle protein breakdown 
As high producing dairy cows are in a state of energy deficiency during early lactation, 
breakdown of muscle protein occurs and plasma concentration of released methylated 
AA increases. This has previously been observed in goats (102). Free AA except Car, 
Gly, HPro, MHis and Ser can be used for synthesis of lactose and casein. However, 
Gly, HPro, MHis and Ser showed a strong increase during the first wk after delivery 
and leads to anabolic state. Gly (both groups) and MHis (CLA group) increased by 60 
%. HPro (CLA group) and Ser (both groups) rose after birth up to 38 % from the base 
value. Plasma MHis (the sum of 1- and 3-MHis) is a derivative of histidine which is 
found in contractile muscles, when His is methylated after incorporation into actin and 
myosin (103). Its plasma and urine concentrations are considered as markers of 
muscle protein breakdown. MHis was measured as the sum of 1- and 3-methylhistidine 
due to insufficient chromatographic separation by the LC-MS/MS method used. Our 
study showed a high and fast increase of MHis ap, which peaked in the first wk after 
delivery, decreased sharply until wk 6 and remained stable from that time onwards. 
This observation is in line with results of Blum et al., 1985 who determined 3-
methylhistidine in lactating cows (103) and observed the same time course of the AA 
profile but with higher absolute concentrations of MHIs than in our study. This 
observation can be explained by its release from catabolized muscle protein during 
negative energy balance. Also feed restriction causes increased plasma leves of MHis 
in lactating cows (101). During delivery and milk production, AA requirements 
exceeding intake are compensated by muscle protein breakdown, which leads to 
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elevated 3-methylhistidine levels as MHis is not a precursor for protein synthesis. 
Almeida et al., 2008, reported similar MHis profiles in lactating goats (capra hircu) 
(102). A further reason for the high plasma concentration of MHis and also HPro, might 
be related to their non proteinogenic character. These AA can not be used for protein 
building or synthesis of lactose and casein which is a major task after delivery. The 
increase after calving around the first wk was also noticed for Gly, HPro and Ser. It 
seems that the degradation of muscle proteins and the release of free AA also 
influenced Gly, HPro and Ser levels. In collagen, Gly and HPro are known to be an 
major AA and increased plasma levels might indicate as an indicator of collagen 
breakdown (104). Increases of Gly and Ser are known but not fully explained. Some 
authors explained the increase of Gly with mobilization of extrahepatic protein (105, 
106). Studies with low protein diet also showed elevated Gly concentration after calving 
(106). The excess of Gly may be needed for milk protein production (107). Ser is a 
precursor of glycerate-3-phosphate and can create Gly and Cys. After delivery, Gly and 
Ser are concentrated in plasma and may be not be used for gluconeogenesis. 
Onwards, concentrations decreased, so Ser and Gly may be utilized for production of 
glycerate-3-phosphate during gluconeogenesis. 
 
4.4.2.3 Plasma Glu decreased dramatically after delivery 
The pronounced decrease of Glu in plasma (around 50% in both groups) may possibly 
be associated with the very high concentrations of free Glu in milk (300 – 650 µmol/L). 
Interestingly, plasma Glu concentrations show high values before parturition and 
decrease strongly after parturition. The reason is unknown, but it might be that the 
fetus is supplied with free Glu from plasma. After parturition, free Glu concentration in 
plasma strongly dropped which may indicate selective transport of Glu into milk. Glu is 
required for the synthesis of casein and whey proteins, as it is one of the major 
components of casein (25 -30%) (Kaufmann et al. 1987). The strong decrease in 
plasma agrees with the hypothesis that Glu and Gln are the limiting AA for casein 
synthesis (108). Windmueller et al., 1974 explained the drop off Gln by the increased 
demand from the gut (109). Key processes like the transfer of the amino group of an 
AA, in which the amino group is mostly transferred to alpha-ketoglutarate. Maybe an 
increased requirement of the calf makes high Glu values necessary in milk. 
 
APPLICATION IN DAIRY SCIENCE 
54 
 
4.5 Conclusion 
With our new developed method, we quantified AA of plasma and milk samples in dairy 
cows of CLA supplemented cows. CLA interventions have been studied in some 
parameters e.g. milk fat in dairy cows whereby the effect on AA is unknown. We 
classified time courses in three different time groups where most AA (Ala, Arg, Asn, 
Asp, Cit, His, Ile, Leu, Lys, Met, Orn, Pro, Thr, Trp, Tyr, Val) decreased up to delivery 
and increased slowly to their basal values. The energy deficit during early lactation 
leads to a catabolic state characterize by fat loss and breakdown of tissue protein. 
Especially muscle protein is degraded, which becomes obvious by increasing plasma 
MHis levels. Released AA especially Glu is used as substrates for synthesis of casein 
and lactose which is needed for the calf. Gly, HPro and Ser showed a strong increase 
during the first wk after delivery and leads to anabolic state. Increased plasma levels of 
Gly and HPro might indicate as an indicator of collagen breakdown. Our analysis 
shows no intervention effect on free plasma and milk AA. Due to stressful delivery we 
only observed a time effect which influence plasma AA concentrations. This suggests 
that CLA supplement did not affect AA precursors for gluconeogenesis and AA 
synthesis during early lactation.  
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5 Summary 
 
Clinical studies show that the composition of circulating free AA in blood, are a marker 
for monogenetic and multigenetic diseases. The analysis of a large number of subjects 
in clinical trials is often limited by complicated and long sample preparation steps. As 
part of the metabolomics platform established at the Dr. von Hauner Children´s 
Hospital, a high-throughput method was developed which allows a selective, sensitive, 
precise and robust quantification of 22 AA from very small sample volumes. Over time 
further AA were added to the methodology.  All AA of 96 samples can be measured 
within 36 hours. Using an internal standard in methanolic solution proteins were 
precipitated from only 10 µL sample volume. For AA quantification, the evaporated 
supernatant is derivatized and analyzed with an ion-pair reagent. The methodology is 
based on a comprehensive and detailed validation with an interday precision of 3.1-
10.8% for all analytes. Every year we participate in a collaborative study which ensures 
an accurate determination of all analytes.  
In the context of early programming, the newly developed AA method was used for 
quantifying 726 serum samples in a randomized clinical trial.  Here, the relation 
between different protein intake (formula with high or low protein content) and AA 
profiles at 6 month old infants was analyzed. A significant alteration in serum 
concentration was found in the HP group for following AA: BCAA, Gly, Lys, Met, Phe, 
Pro, Thr, Trp und Tyr. Essential AA were taken by nutrients and probably released from 
the L-transport system into circulation. In comparison, non essential AA are catabolized 
in the intestine and regulated by de novo synthesis in equal concentrations. Therefore, 
no significant difference of non essential AA was observed between HP and LP group. 
High protein diet leads to an activation of growth hormones (mTOR, IGF-1) by 
enhanced availability of AA which is manifested in increased cell growth and 
proliferation. Nevertheless, the increased hormone activation can causes diseases 
such as insulin resistance, diabetes or obesity. Because of the increased risk for 
diseases a high protein diet in early infancy is not recommended but breast feeding or 
low protein diet can have beneficial effects for health.  
Within a cow supplementation project, the newly developed AA method has proved 
effective. From two weeks before to nine weeks after expected calving one group (CLA 
group, n=10) was supplemented with CLA and one group (control group, n=10) was 
supplemented with linoleic acid. The aim of the study was to analyze the relation 
between CLA supplementation and AA profiles in blood samples. These were taken at 
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a total of eight times before and after delivery. We observed three different time 
courses of AA. In most cases AA levels decreased after delivery and afterwards 
concentrations increased slowly to their initial values. Glu is decreased before delivery 
which may indicate that the fetus is supplied sufficient with Glu. After delivery Glu is 
increasingly transported in the milk. Gly, HPro, MHis and Ser increased after delivery 
and then moved back to basal values where MHis did not increase in the first 12 weeks 
due to muscle protein breakdown. CLA supplementation showed no significant 
difference between the two groups on the AA concentrations and thus showed no 
effect on AA synthesis. 
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6 Zusammenfassung 
 
Klinische Studien zeigen, dass die Zusammensetzung von zirkulierenden, freien AS im 
Blut, ein Marker für monogene und multigenetische Krankheiten ist. Die Analyse von 
hohen Probandenzahlen in klinischen Studien wird oftmals durch aufwendige und 
lange Probenaufarbeitungsschritte begrenzt. Im Rahmen der Metabolomics Plattform, 
die im Dr. von Haunerschen Kinderspitals etabliert wurde, wurde eine 
Hochdurchsatzmethode entwickelt, die eine selektive, sensitive, präzise und robuste 
Quantifizierung von 22 AS aus kleinen Probenvolumina ermöglicht. Im Laufe der Zeit 
konnten noch weitere Aminosäuren zur Methodik hinzugefügt werden. Dabei können 
innerhalb von 36 Stunden 96 Proben analysiert werden. Mit Hilfe eines deuterierten, 
interenen Standards in methanolischer Lösung werden Proteine aus nur 10 µL 
Probenvolumen gefällt. Zur Quantifizierung der AS wird anschliessend der 
eingedampfte Überstand derivatisiert und in Kombination mit einem Ionen-Paar-
Reagenzes chromatographiert. Der Methodenaufarbeitung liegt eine umfassende und 
ausführliche Validierung zugrunde, die einer Interday Precision von 3.1 -10.8 % für alle 
Analyten erzielt. Zusätzlich unterzieht sich unsere Methode jedes Jahr an einem 
Ringversuch, der eine exakte Bestimmung aller Analyten gewährleistet.  
Im Zusammenhang mit der Programmierung des Stoffwechsels durch die Ernährung 
im Säuglingsalter wurde die neu entwickelte AS-Methode zur Quantifizierung von 726 
Serum Proben in einer randomizierten klinischen Studie eingesetzt. Dabei wurde der 
Bezug zwischen Proteinzufuhr (Formelnahrung mit hohem Eiweißanteil bzw. 
niedriegem Eiweißanteil) und AS-Profil bei 6 Monate alten Säuglingen analysiert. Eine 
signifikante Veränderung der Plasmakonzentrationen zeigte sich in der Gruppe der 
formelernährten Kindern mit hohem Proteinanteil für folgende AS: BCAA, Gly, Lys, 
Met, Phe, Pro, Thr, Trp und Tyr. Essentielle AS werden über die Nahrung 
aufgenommen und vermutlich über das L-Transportsystem in die Zirkulation 
freigesetzt. Im Vergleich dazu werden nicht essentielle AS im Darm katabolisiert und 
mit Hilfe der de novo Synthese in gleichbleibenden Konzentrationen reguliert, sodass 
kein signifikanter Unterschied in beiden Gruppen beobachtet wurde. Durch eine 
proteinreiche Nahrung können AS vermehrt an der Aktivierung von 
Wachstumshormonen (mTOR, IGF-1) teilhaben, was sich im vermehrten Zellwachstum 
und –proliferation manifestiert. Nichts desto trotz kann die vermehrte 
Wachstumshormonaktivierung Krankheiten wie Insulinresistenz, Diabetes oder auch 
Übergewicht hervorrufen. Aufgrund des erhöhten Krankheitsrisikos ist einerseits von 
einer proteinreichen Ernährung im frühen Säuglingsalter abzuraten, andererseits kann 
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das Stillen bzw. eiweißänhnliche Brustmilchzusammensetzung   
gesundheitsunterstützend sein.  
Auch im Rahmen eines Supplementierungsprojektes bei Kühen, hat sich die neu 
entwickelte AS-Methode bewährt. Dazu wurden jeweils 10 Kühe kurz vor und nach der 
Geburt mit CLA (CLA-Gruppe) oder mit Linolsäure (Kontroll-Gruppe) supplementiert. 
Ziel der Studie war es, den Zusammenhang zwischen CLA Supplementierung und AS-
Profil im Blut zu analysieren. Dazu wurden zu insgesamt 8 Zeitpunkten vor und nach 
der Geburt, Blutproben entnommen. Es kristallisierten sich 3 verschiedene Zeitverläufe 
heraus, wobei die meisten AS-Konzentrationen nach der Geburt abfallen und langsam 
wieder auf ihre Ausgangswerte ansteigen. AS wie Glu sinken vor der Geburt stark ab, 
was dafür sprechen könnte, dass der Fetus mit ausreichend Glu versorgt wird und 
nach der Geburt vermehrt in die Milch transportiert wird. Gly, HPro, MHis und Ser 
steigen bis zur Geburt an und fallen dann wieder ab wobei Mhis durch den 
Muskelproteinabbau keinen Konzentrationsanstieg in den ersten 12 Laktationswochen 
erfährt. Die Supplementierung mit CLA zeigte keinen signifikanten Unterschied beider 
Gruppen auf das AS-Profil und zeigte somit keine Auswirkungen auf die AS-Synthese.  
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8 Appendex 
Table 1: AA concentration of CLA supplemented cows. All results presented as mean  
CLA 
group week -2  week 1 week 2 week 3 week 4 week 6 week 9 week 12 
AA   
Mean 
 [µmol/L] 
 
SE 
[µmol/L] 
Mean 
 [µmol/L] 
 
SE 
[µmol/L] 
Mean 
 [µmol/L] 
 
SE 
[µmol/L] 
Mean  
[µmol/L] 
 
SE 
[µmol/L] 
Mean  
[µmol/L] 
 
SE  
[µmol/L] 
Mean 
 [µmol/L] 
 
SE  
[µmol/L] 
Mean  
[µmol/L] 
 
SE 
[µmol/L] 
Mean 
 [µmol/L] 
 
SE 
[µmol/L] 
Ala 291 ± 18.9 216.9 ± 10.4 226.3 ± 16.9 256.4 ± 16.5 245.3 ± 21.8 272.1 ± 22.6 267.1 ± 19.7 280.2 ± 17.9 
Arg 64.3 ± 5.1 43.9 ± 4.7 55.3 ± 4.6 60.9 ± 5 59.2 ± 5.4 68.3 ± 9.4 73.4 ± 9.4 91.4 ± 6.9 
Asn 24.4 ± 3.6 22.9 ± 3.3 32.5 ± 4.5 37.5 ± 3.5 36.3 ± 4 37.1 ± 4.7 39.4 ± 4.8 42 ± 3.7 
Asp 7 ± 0.7 5.1 ± 0.6 6.5 ± 0.7 8 ± 0.7 7.5 ± 0.4 8.4 ± 0.7 8.9 ± 0.8 10.3 ± 0.5 
Car 5.8 ± 1.9 9 ± 3 8.8 ± 2.9 9.8 ± 3.3 10 ± 3.3 10.5 ± 3.5 12 ± 4 11.9 ± 4 
Cit 73.7 ± 5.9 64.2 ± 3.5 73.4 ± 5.2 85.9 ± 5.7 83.4 ± 7.5 93.2 ± 7.9 87.2 ± 9.5 95.6 ± 7.4 
Cysta 2.1 ± 0.3 2.8 ± 0.1 2.8 ± 0.1 3 ± 0.1 2.8 ± 0.1 2.6 ± 0.3 3.1 ± 0.1 3.2 ± 0.1 
Gln 292 ± 22.2 286 ± 21.6 246.7 ± 20.6 232.6 ± 15.4 234 ± 14.6 236.7 ± 26.3 259.7 ± 24.5 260.9 ± 23.9 
Glu 87.5 ± 9.4 46.8 ± 4.1 42.5 ± 5.3 41.4 ± 4.4 38.8 ± 2.1 42.2 ± 4.2 38.4 ± 3.1 46.9 ± 3.5 
Gly 261.6 ± 14.4 441.7 ± 43 547.2 ± 30.6 588.1 ± 42.7 554 ± 57.4 429.6 ± 34.3 412.4 ± 32.6 407.4 ± 29.5 
His 56 ± 5.1 50.2 ± 8 51.1 ± 5 45.8 ± 5.5 53.3 ± 5.6 52.8 ± 7.7 55.7 ± 5.6 59.3 ± 4.5 
HLys 0.8 ± 0.1 0.8 ± 0.2 0.4 ± 0 0.4 ± 0.1 0.4 ± 0 0.4 ± 0.1 0.4 ± 0 0.4 ± 0.1 
HPro 21.5 ± 1.4 26.3 ± 2.3 25.9 ± 2.1 23.2 ± 1.1 19.9 ± 1.3 21.9 ± 1.7 23.1 ± 2.3 20.9 ± 2.1 
Ile 98 ± 7.6 69.9 ± 8.3 96.1 ± 7.7 111 ± 13.6 114.6 ± 10.3 108 ± 12.6 99.3 ± 13.8 114.3 ± 12.1 
Leu 134.5 ± 7.7 92.5 ± 7.4 119.6 ± 8.3 126.9 ± 14.5 131.5 ± 10.6 124.6 ± 14.1 121.9 ± 17 137.7 ± 12.3 
Lys 81 ± 7.5 47.3 ± 3.9 62.3 ± 5 71.7 ± 6.1 64.8 ± 3.3 67.3 ± 6.5 64.4 ± 6.6 82 ± 6.2 
Met 26.3 ± 2.1 20.5 ± 1.4 22.7 ± 1.9 22.9 ± 2.1 20.5 ± 1.8 20 ± 2.5 22 ± 2.3 24 ± 1.5 
MHis 7.5 ± 0.6 12.7 ± 1.1 8.7 ± 1 5.9 ± 0.5 5.4 ± 0.4 4.3 ± 0.3 4.3 ± 0.3 4.3 ± 0.3 
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Orn 41.4 ± 4.9 17.2 ± 2.9 21.9 ± 2.8 26.4 ± 3.6 30 ± 4.1 32.3 ± 5.7 35.9 ± 6.1 45.5 ± 4.5 
Phe 55.5 ± 2.2 40.7 ± 3 48.1 ± 2.4 43.4 ± 2.3 41 ± 2 43.4 ± 3.1 44.1 ± 4 47 ± 3.6 
Pro 107.7 ± 7.8 90.7 ± 10.3 109.3 ± 11.1 119.2 ± 11.1 113 ± 11.2 117.2 ± 16.3 123.5 ± 12.2 129.3 ± 9.1 
Ser 80.5 ± 6.4 111.1 ± 11.6 110.2 ± 8 106.6 ± 8.2 98 ± 8.1 99.9 ± 6.7 93 ± 7.4 94.9 ± 7.7 
Thr 95.3 ± 11 54.6 ± 9.4 70.9 ± 8.3 86.8 ± 6.8 90.5 ± 8.1 90.8 ± 10 93.2 ± 13 97.1 ± 5 
Trp 49.7 ± 5.7 25.6 ± 3.5 35.1 ± 3 3.3 39.5 ± 3.8 39.6 ± 4.6 53.6 ± 3.7 55.9 ± 4 56.7 ± 3.1 
Tyr 51.1 ± 4.3 30.3 ± 1.7 38.3 ± 4.3 40.3 ± 2.6 38.4 ± 3.6 46.8 ± 4.9 45.8 ± 6.1 46.7 ± 4.6 
Val 234.2 ± 16.7 169.9 ± 18.1 234.2 ± 23 249.3 ± 25.7 273.8 ± 25.9 269.9 ± 29.4 258.5 ± 27.9 281.9 ± 17.9 
 
Table 2: AA concentration of cows in control group. All results presented as mean  
Control 
group week -2  week 1 week 2 week 3 week 4 week 6 week 9 week 12 
 
 
  AA 
Mean 
 [µmol/L] 
 
SE 
[µmol/L] 
Mean 
 [µmol/L] 
 
SE 
[µmol/L] 
Mean 
 [µmol/L] 
 
SE 
[µmol/L] 
Mean 
[µmol/L] 
 
SE 
[µmol/L] 
Mean  
[µmol/L] 
 
SE  
[µmol/L] 
Mean 
 [µmol/L] 
 
SE  
[µmol/L] 
Mean  
[µmol/L] 
 
SE 
[µmol/L] 
Mean 
 [µmol/L] 
 
SE 
[µmol/L] 
Ala 293.1 ± 24.3 241.4 ± 18.7 244.8 ± 19.4 242.4 ± 19.7 259.5 ± 25.6 249.8 ± 16.3 257.6 ± 15.5 260.9 ± 14.9 
Arg 71.2 ± 5.2 48.3 ± 4.5 59.2 ± 4.9 64.9 ± 7.5 69.8 ± 5.8 81.4 ± 8.6 80.2 ± 6.6 86.4 ± 6.3 
Asn 27.3 ± 2.6 27.4 ± 4.1 38.9 ± 3.9 38.1 ± 3.5 41.6 ± 3.6 39.1 ± 4 43.2 ± 4.5 38.6 ± 2.8 
Asp 7.8 ± 0.8 7 ± 1.3 7.2 ± 0.5 7.8 ± 0.4 8.4 ± 0.5 9.7 ± 0.8 10.3 ± 0.7 11.5 ± 0.9 
Car 7.6 ± 0.8 8.8 ± 1.1 11.7 ± 1.2 13.5 ± 1.1 12.3 ± 1 11.3 ± 1.2 12.9 ± 1 13.2 ± 1.6 
Cit 87 ± 4.4 78.5 ± 8.4 88.4 ± 7.4 92.6 ± 8.5 91.4 ± 4.5 89.4 ± 10.3 87 ± 9.2 90.2 ± 6.1 
Cysta 2.2 ± 0.3 2.6 ± 0.3 3 ± 0.1 3.1 ± 0.1 3.2 ± 0.1 3.3 ± 0.2 3.3 ± 0.1 2.9 ± 0.3 
Gln 296.2 ± 14.9 253.2 ± 17.1 245.9 ± 19.8 240.6 ± 20.5 244.5 ± 18.7 224.3 ± 13.9 244.7 ± 23.3 254.7 ± 18.3 
Glu 120.1 ± 13.9 56.6 ± 11.7 51.6 ± 4.3 45.3 ± 3.8 43.9 ± 4.7 45.1 ± 5 46 ± 3.1 49.7 ± 6.6 
Gly 327.2 ± 16.8 531.6 ± 57.7 687.3 ± 53.3 680 ± 45.9 653.1 ± 35.1 477.8 ± 40.3 467 ± 38.4 359.4 ± 15 
His 63.8 ± 3.5 46.4 ± 5.1 51 ± 2.7 49.2 ± 4.3 55.6 ± 4.9 52.9 ± 4.9 56.7 ± 5.3 62.1 ± 4.5 
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HLys 0.8 ± 0.1 0.7 ± 0.1 0.6 ± 0.1 0.6 ± 0.1 0.4 ± 0.1 0.3 ± 0 0.3 ± 0.1 0.4 ± 0.1 
HPro 23.8 ± 2 26.6 ± 2.3 25.9 ± 1.7 22.5 ± 1.8 22.5 ± 1.2 20.9 ± 2.3 17.7 ± 1.3 17.9 ± 1.7 
Ile 111.6 ± 7.3 97.8 ± 8.4 106.8 ± 7.4 116.9      ± 16.6 120.2 ± 12.2 110.9 ± 5.8 102.4 ± 8.2 111.3 ± 8.8 
Leu 145 ± 7.1 123.5 ± 9.6 134.8 ± 8.5 130.2 ± 13.5 140.4 ± 11.5 132.2 ± 6.9 121.3 ± 8.8 140.7 ± 9.1 
Lys 90 ± 8.5 58.9 ± 3.9 71.5 ± 6 70.9 ± 5.1 78.5 ± 5.6 80.1 ± 8 82.3 ± 6.7 85.2 ± 5.5 
Met 27.5 ± 1.9 23.5 ± 1.8 25.2 ± 2.1 23 ± 2 23.6 ± 1.7 22.3 ± 2.1 24.1 ± 2.4 25.5 ± 1.8 
MHis 8.8 ± 1 11.3 ± 0.9 8.7 ± 0.5 6.2 ± 0.5 5.3 ± 0.5 4.3 ± 0.3 3.9 ± 0.3 4 ± 0.3 
Orn 50.4 ± 3.8 31 ± 5.4 34.2 ± 5.5 31.8 ± 4.1 33.4 ± 3.4 45.8 ± 5.5 43.9 ± 6.2 48 ± 5.5 
Phe 59 ± 2.8 47.9 ± 1.5 49.6 ± 2.6 42.8 ± 3.7 45.8 ± 3.8 46.4 ± 3.8 43.2 ± 2.7 48.2 ± 2.3 
Pro 120.2 ± 6.3 104.8 ± 9.9 129.7 ± 10.7 124.7 ± 11.3 134.5 ± 15.5 121 ± 8.6 131.8 ± 9.2 129.2 ± 6.9 
Ser 98.2 ± 7.5 126 ± 16.7 126.9 ± 10.2 113.3 ± 8.3 121.5 ± 8.9 99.8 ± 8.8 111.7 ± 6.6 102.2 ± 5 
Thr 100 ± 13 66.6 ± 8.2 85 ± 9.7 91.5 ± 8.2 100.4 ± 8.5 93.5 ± 11.7 116.4 ± 12.3 115.6 ± 9.4 
Trp 58.2 ± 3.8 35.9 ± 4.5 37.1 ± 2.7 45.5 ± 3.3 48.3 ± 3.4 53.4 ± 3.6 60.6 ± 2.6 61.4 ± 5.8 
Tyr 56.3 ± 2.6 43.6 ± 4.4 44.7 ± 4.2 43.7 ± 4.6 50.3 ± 5.6 46.9 ± 5.3 48.7 ± 4.1 57.2 ± 4 
Val 245.3 ± 13.2 218.7 ± 18.7 255 ± 19.2 257.1 ± 
 
288.4 ± 19 267.7 ± 12.2 282.2 ± 18.9 283.5 ± 17.7 
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